eunicebok的个人主页 - 老虎社区

eunicebok

eunicebok

暂无个人介绍

IP属地：未知

5关注

5粉丝

4主题

0勋章

2022-01-04

$KEPPEL DC REIT(AJBU.SI)$2022 ✌️

2021-11-03

Microsoft

2021-11-02

What ww should buy right now?

Warren Buffett says this is the best type of business to own when inflation spikes — in other words, what you should buy right now

2021-11-02

booster

Pfizer rose over 2% in premarket trading as it raised COVID-19 vaccine sales forecast to $36 bln for 2021

2021-09-08

Good question! What to buy now?

Strategists Say the Stock Market Could Struggle This Fall. What to Buy Now?

2021-09-06

$RIVERSTONE HOLDINGS LIMITED(AP4.SI)$ hmmm.... If 👇 again i ll average 👇

2021-09-06

$MAPLETREE INDUSTRIAL TRUST(ME8U.SI)$🤑

2021-09-03

Not sure is it good price to enter, but just do it💪💪

2021-09-03

Good

抱歉，原内容已删除

2021-09-03

Tgif

3 Hypergrowth Stocks Expected to Increase Sales 1,185% to 12,629% by 2023

2021-09-03

$Alibaba(BABA)$💪

2021-09-02

👍👍

抱歉，原内容已删除

2021-09-02

keep going📈

抱歉，原内容已删除

2021-09-02

Good one

Hong Kong: Shares extend gains at open

2021-09-02

No idea

抱歉，原内容已删除

2021-09-02

Well, im newbie to us stocks😅

抱歉，原内容已删除

2021-09-01

$GENTING SINGAPORE LIMITED(G13.SI)$ add on some units

2021-08-30

$MAPLETREE INDUSTRIAL TRUST(ME8U.SI)$💵💵

2021-08-30

$TOP GLOVE CORPORATION BHD(BVA.SI)$ please turn green soon...

2021-08-28

💪💪💪

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3578570980039527","uuid":"3578570980039527","gmtCreate":1615476956157,"gmtModify":1627553474199,"name":"eunicebok","pinyin":"eunicebok","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":5,"headSize":5,"tweetSize":25,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":4,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.12.09","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.11.15","exceedPercentage":"60.75%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":695076904,"gmtCreate":1641281563724,"gmtModify":1641281563817,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AJBU.SI\">$KEPPEL DC REIT(AJBU.SI)$</a>2022 ✌️&nbsp;","listText":"<a href=\"https://laohu8.com/S/AJBU.SI\">$KEPPEL DC REIT(AJBU.SI)$</a>2022 ✌️&nbsp;","text":"$KEPPEL DC REIT(AJBU.SI)$2022 ✌️","images":[{"img":"https://static.tigerbbs.com/cd8582f3e2978617459b65a97d70b493","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/695076904","isVote":1,"tweetType":1,"viewCount":523,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":841968365,"gmtCreate":1635868992052,"gmtModify":1635870189623,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"Microsoft&nbsp;","listText":"Microsoft&nbsp;","text":"Microsoft","images":[{"img":"https://static.tigerbbs.com/69cebd20c1d6ea22ad18eabcc33a19b2","width":"1080","height":"3083"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/841968365","isVote":1,"tweetType":1,"viewCount":426,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":841987481,"gmtCreate":1635868657061,"gmtModify":1635868657061,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"What ww should buy right now?&nbsp;","listText":"What ww should buy right now?&nbsp;","text":"What ww should buy right now?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/841987481","repostId":"2180020937","repostType":4,"repost":{"id":"2180020937","kind":"news","pubTimestamp":1635846331,"share":"https://www.laohu8.com/m/news/2180020937?lang=&edition=full","pubTime":"2021-11-02 17:45","market":"us","language":"en","title":"Warren Buffett says this is the best type of business to own when inflation spikes — in other words, what you should buy right now","url":"https://stock-news.laohu8.com/highlight/detail?id=2180020937","media":"MoneyWise","summary":"Inflation is high. You might as well profit from it.High inflation rates in the country have become a serious concern on Wall Street.But fortunately for everyday investors, Berkshire Hathaway chief Warren Buffett has plenty of experience in navigating such an environment.Buffett managed a stock portfolio through periods of double-digit inflation rates in the 1970s and has plenty of advice on what to own when consumer prices spike.In a 1981 letter to Berkshire shareholders, Buffett highlighted tw","content":"<p>Inflation is high. You might as well profit from it.</p>\n<p><img src=\"https://static.tigerbbs.com/143c38befb27f09743294aafaffbe94a\" tg-width=\"1800\" tg-height=\"800\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>High inflation rates in the country have become a serious concern on Wall Street.</p>\n<p>But fortunately for everyday investors, Berkshire Hathaway chief Warren Buffett has plenty of experience in navigating such an environment.</p>\n<p>Buffett managed a stock portfolio through periods of double-digit inflation rates in the 1970s and has plenty of advice on what to own when consumer prices spike.</p>\n<p>In a 1981 letter to Berkshire shareholders, Buffett highlighted two characteristics that make a business well adapted to an inflationary environment: 1) an ability to increase prices easily, and 2) an ability to take on more business without having to spend too much in order to do it.</p>\n<p>In other words, aim to invest in asset-light businesses with pricing power.</p>\n<p>Let’s take a quick look at three companies that fit that description. One (or all) of them might be worth purchasing with your spare pennies.</p>\n<p><b>Nike (NKE)</b></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0a24fd7cb9b4e01313c7bb848af6da9d\" tg-width=\"1200\" tg-height=\"500\" width=\"100%\" height=\"auto\"><span>TY Lim/Shutterstock</span></p>\n<p>Nike is a global footwear powerhouse that commands high customer loyalty.</p>\n<p>Customers are willing to pay top dollar for signature gear associated with high-profile athletes like LeBron James and Michael Jordan.</p>\n<p>Despite inflationary pressures, Nike continues to expand gross margins and post solid returns on equity well above 30%.</p>\n<p>The company is also capturing the full price of its products in an increasingly digital, direct-to-consumer business model.</p>\n<p>Management believes digital sales could continue to grow from 20% of revenue currently to about 40% of the business by 2025. And price increases could kick in as early as next year.</p>\n<p>Amazingly, profit margins may keep expanding, even as operating costs rise with inflation.</p>\n<p>Nike shares are up about 19% so far in 2021.</p>\n<p><b>Apple (AAPL)</b></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b22460a66469a2da0380edd32d454c84\" tg-width=\"1200\" tg-height=\"500\" width=\"100%\" height=\"auto\"><span>Vytautas Kielaitis/Shutterstock</span></p>\n<p>Global demand for Apple’s premium-priced hardware is growing, as are adoption rates for its high-margin Apple services.</p>\n<p>Strong brand identity, user friendliness, and a wide range of fully integrated products are powerful attributes that aren’t going away any time soon.</p>\n<p>Customers just can’t afford to live outside the Apple ecosystem. That gives the tech giant more freedom to play with pricing as inflation spikes.</p>\n<p>The company’s latest M1 chips, which will gradually replace Intel’s CPUs in every single Mac, underscore its commitment to constant innovation.</p>\n<p>Apple’s ability to pass rising costs to a global consumer base without significant loss of sales volumes is undeniable.</p>\n<p>Warren Buffett has allowed Apple to grow to 40% of Berkshire Hathaway’s investments portfolio for good reason: The business just keeps growing profits through all economic cycles.</p>\n<p>Apple is up about 13% year to date and trades at nearly $150 per share. But if you’re on the fence about jumping in at the current level, some apps might give you a free share of Apple just for signing up.</p>\n<p><b>Levi Strauss &amp; Co. (LEVI)</b></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/71b31165e275a966ad050139a054c73a\" tg-width=\"1200\" tg-height=\"500\" width=\"100%\" height=\"auto\"><span>dean bertoncelj/Shutterstock</span></p>\n<p>A market leader in the denim business, Levi Strauss has been firing on all cylinders of late.</p>\n<p>Specifically, its well-known brand and a flexible business model have enabled management to grow the top line without sacrificing pricing power.</p>\n<p>In the most recent quarter, revenue increased 41% while adjusted gross margin improved 390 basis points to 57.5%.</p>\n<p>In fact, management proactively started adjusting its pricing for inflation back in 2020.</p>\n<p>The company also sources raw materials from 24 different countries. And that kind of supply chain diversification provides Levi Strauss with plenty of flexibility during times of crisis.</p>\n<p>Levi shares are up more than 30% in 2021.</p>\n<p><b>The ultimate 'forever asset'?</b></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d5d520eb27cdf18f25a787cd9145eb1b\" tg-width=\"1200\" tg-height=\"500\" width=\"100%\" height=\"auto\"><span>MNStudio/Shutterstock</span></p>\n<p>Warren Buffett once said that his favorite holding period is forever.</p>\n<p>But forever is a long time, and since companies rise and fall, growing your wealth by never selling a share may not be the best strategy.</p>\n<p>But there might be one inflation safe haven that's worth holding forever — U.S. farmland.</p>\n<p>No matter how high or fast consumer prices climb, people still need to eat. And it just so happens that Buffett’s good friend Bill Gates is America’s largest private owner of farmland.</p>\n<p>These days, new platforms allow you to invest in U.S. farmland by taking stake in a farm of your choice.</p>\n<p>You’ll earn cash income from the leasing fees and crop sales. And of course, you’ll benefit from any long-term appreciation on top of that.</p>\n<p><i>This article provides information only and should not be construed as advice. It is provided without warranty of any kind.</i></p>","source":"lsy1621813427262","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Warren Buffett says this is the best type of business to own when inflation spikes — in other words, what you should buy right now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWarren Buffett says this is the best type of business to own when inflation spikes — in other words, what you should buy right now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-02 17:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://moneywise.com/investing/stocks/warren-buffett-inflation-stocks><strong>MoneyWise</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Inflation is high. You might as well profit from it.\n\nHigh inflation rates in the country have become a serious concern on Wall Street.\nBut fortunately for everyday investors, Berkshire Hathaway chief...</p>\n\n<a href=\"https://moneywise.com/investing/stocks/warren-buffett-inflation-stocks\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BRK.B":"伯克希尔B","INTC":"英特尔","NKE":"耐克","AAPL":"苹果","BRK.A":"伯克希尔","LEVI":"李维斯"},"source_url":"https://moneywise.com/investing/stocks/warren-buffett-inflation-stocks","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2180020937","content_text":"Inflation is high. You might as well profit from it.\n\nHigh inflation rates in the country have become a serious concern on Wall Street.\nBut fortunately for everyday investors, Berkshire Hathaway chief Warren Buffett has plenty of experience in navigating such an environment.\nBuffett managed a stock portfolio through periods of double-digit inflation rates in the 1970s and has plenty of advice on what to own when consumer prices spike.\nIn a 1981 letter to Berkshire shareholders, Buffett highlighted two characteristics that make a business well adapted to an inflationary environment: 1) an ability to increase prices easily, and 2) an ability to take on more business without having to spend too much in order to do it.\nIn other words, aim to invest in asset-light businesses with pricing power.\nLet’s take a quick look at three companies that fit that description. One (or all) of them might be worth purchasing with your spare pennies.\nNike (NKE)\nTY Lim/Shutterstock\nNike is a global footwear powerhouse that commands high customer loyalty.\nCustomers are willing to pay top dollar for signature gear associated with high-profile athletes like LeBron James and Michael Jordan.\nDespite inflationary pressures, Nike continues to expand gross margins and post solid returns on equity well above 30%.\nThe company is also capturing the full price of its products in an increasingly digital, direct-to-consumer business model.\nManagement believes digital sales could continue to grow from 20% of revenue currently to about 40% of the business by 2025. And price increases could kick in as early as next year.\nAmazingly, profit margins may keep expanding, even as operating costs rise with inflation.\nNike shares are up about 19% so far in 2021.\nApple (AAPL)\nVytautas Kielaitis/Shutterstock\nGlobal demand for Apple’s premium-priced hardware is growing, as are adoption rates for its high-margin Apple services.\nStrong brand identity, user friendliness, and a wide range of fully integrated products are powerful attributes that aren’t going away any time soon.\nCustomers just can’t afford to live outside the Apple ecosystem. That gives the tech giant more freedom to play with pricing as inflation spikes.\nThe company’s latest M1 chips, which will gradually replace Intel’s CPUs in every single Mac, underscore its commitment to constant innovation.\nApple’s ability to pass rising costs to a global consumer base without significant loss of sales volumes is undeniable.\nWarren Buffett has allowed Apple to grow to 40% of Berkshire Hathaway’s investments portfolio for good reason: The business just keeps growing profits through all economic cycles.\nApple is up about 13% year to date and trades at nearly $150 per share. But if you’re on the fence about jumping in at the current level, some apps might give you a free share of Apple just for signing up.\nLevi Strauss & Co. (LEVI)\ndean bertoncelj/Shutterstock\nA market leader in the denim business, Levi Strauss has been firing on all cylinders of late.\nSpecifically, its well-known brand and a flexible business model have enabled management to grow the top line without sacrificing pricing power.\nIn the most recent quarter, revenue increased 41% while adjusted gross margin improved 390 basis points to 57.5%.\nIn fact, management proactively started adjusting its pricing for inflation back in 2020.\nThe company also sources raw materials from 24 different countries. And that kind of supply chain diversification provides Levi Strauss with plenty of flexibility during times of crisis.\nLevi shares are up more than 30% in 2021.\nThe ultimate 'forever asset'?\nMNStudio/Shutterstock\nWarren Buffett once said that his favorite holding period is forever.\nBut forever is a long time, and since companies rise and fall, growing your wealth by never selling a share may not be the best strategy.\nBut there might be one inflation safe haven that's worth holding forever — U.S. farmland.\nNo matter how high or fast consumer prices climb, people still need to eat. And it just so happens that Buffett’s good friend Bill Gates is America’s largest private owner of farmland.\nThese days, new platforms allow you to invest in U.S. farmland by taking stake in a farm of your choice.\nYou’ll earn cash income from the leasing fees and crop sales. And of course, you’ll benefit from any long-term appreciation on top of that.\nThis article provides information only and should not be construed as advice. It is provided without warranty of any kind.","news_type":1},"isVote":1,"tweetType":1,"viewCount":680,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":843734429,"gmtCreate":1635858032191,"gmtModify":1635858032191,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"booster","listText":"booster","text":"booster","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/843734429","repostId":"1193558756","repostType":4,"repost":{"id":"1193558756","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635850584,"share":"https://www.laohu8.com/m/news/1193558756?lang=&edition=full","pubTime":"2021-11-02 18:56","market":"us","language":"en","title":"Pfizer rose over 2% in premarket trading as it raised COVID-19 vaccine sales forecast to $36 bln for 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=1193558756","media":"Tiger Newspress","summary":"Pfizer Inc on Tuesday raised the full-year sales forecast for its COVID-19 vaccine by 7.5% to $36 bi","content":"<p>Pfizer Inc&nbsp;on Tuesday raised the full-year sales forecast for its COVID-19 vaccine by 7.5% to $36 billion, as it signs deals with countries for booster doses and receives clearances for using its shots in children.</p>\n<p>The company had in July forecast sales of $33.5 billion from the vaccine it sells with BioNTech .</p>\n<p>Driven by an unprecedented vaccination drive against the COVID-19 pandemic globally, Pfizer's shot has quickly become one of the best-selling products in the company's roughly 172-year history.</p>\n<p>The company, which was well known for drugs such as Xanax and Viagra, equally splits expenses and profit with its German partner.</p>\n<p>Pfizer expects to deliver 2.3 billion doses of the vaccine, out of the roughly 3 billion it expects to make this year.</p>\n<p>Its&nbsp;shares&nbsp;rose&nbsp;over 2% in premarket trading.<img src=\"https://static.tigerbbs.com/df663bc64292fce6036a0c102eb67471\" tg-width=\"770\" tg-height=\"566\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer rose over 2% in premarket trading as it raised COVID-19 vaccine sales forecast to $36 bln for 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer rose over 2% in premarket trading as it raised COVID-19 vaccine sales forecast to $36 bln for 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-02 18:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pfizer Inc&nbsp;on Tuesday raised the full-year sales forecast for its COVID-19 vaccine by 7.5% to $36 billion, as it signs deals with countries for booster doses and receives clearances for using its shots in children.</p>\n<p>The company had in July forecast sales of $33.5 billion from the vaccine it sells with BioNTech .</p>\n<p>Driven by an unprecedented vaccination drive against the COVID-19 pandemic globally, Pfizer's shot has quickly become one of the best-selling products in the company's roughly 172-year history.</p>\n<p>The company, which was well known for drugs such as Xanax and Viagra, equally splits expenses and profit with its German partner.</p>\n<p>Pfizer expects to deliver 2.3 billion doses of the vaccine, out of the roughly 3 billion it expects to make this year.</p>\n<p>Its&nbsp;shares&nbsp;rose&nbsp;over 2% in premarket trading.<img src=\"https://static.tigerbbs.com/df663bc64292fce6036a0c102eb67471\" tg-width=\"770\" tg-height=\"566\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1193558756","content_text":"Pfizer Inc on Tuesday raised the full-year sales forecast for its COVID-19 vaccine by 7.5% to $36 billion, as it signs deals with countries for booster doses and receives clearances for using its shots in children.\nThe company had in July forecast sales of $33.5 billion from the vaccine it sells with BioNTech .\nDriven by an unprecedented vaccination drive against the COVID-19 pandemic globally, Pfizer's shot has quickly become one of the best-selling products in the company's roughly 172-year history.\nThe company, which was well known for drugs such as Xanax and Viagra, equally splits expenses and profit with its German partner.\nPfizer expects to deliver 2.3 billion doses of the vaccine, out of the roughly 3 billion it expects to make this year.\nIts shares rose over 2% in premarket trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":533,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":880828029,"gmtCreate":1631035271361,"gmtModify":1632904431077,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"Good question! What to buy now?&nbsp;","listText":"Good question! What to buy now?&nbsp;","text":"Good question! What to buy now?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/880828029","repostId":"1130130857","repostType":4,"repost":{"id":"1130130857","kind":"news","pubTimestamp":1631007146,"share":"https://www.laohu8.com/m/news/1130130857?lang=&edition=full","pubTime":"2021-09-07 17:32","market":"us","language":"en","title":"Strategists Say the Stock Market Could Struggle This Fall. What to Buy Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=1130130857","media":"Barron's","summary":"What a year this has been for the markets!Fueled by a torrent of monetary and fiscal stimulus, economic and earnings growth, and  a mostly receding pandemic, theS&P 500stock index has rallied 20%, notching seven straight months of gains and more than 50 highs along the way. And that’s on top of last year’s 68% rebound from the market’s March 2020 lows.Tailwinds remain in place, but headwinds now loom that could slow stocks’ advance. Stimulus spending has peaked, and economic and corporate-earnin","content":"<p>What a year this has been for the markets! Fueled by a torrent of monetary and fiscal stimulus, economic and earnings growth, and (until recently) a mostly receding pandemic, theS&amp;P 500stock index has rallied 20%, notching seven straight months of gains and more than 50 highs along the way. And that’s on top of last year’s 68% rebound from the market’s March 2020 lows.</p>\n<p>Tailwinds remain in place, but headwinds now loom that could slow stocks’ advance. Stimulus spending has peaked, and economic and corporate-earnings growth are likely to decelerate through the end of the year. What’s more, theFederal Reserve has all but promised to start tapering its bond buyingin coming months, and the Biden administration has proposed hiking corporate and personal tax rates. None of this is apt to sit well with holders of increasingly pricey shares.</p>\n<p>In other words,brace for a volatile fallin which conflicting forces buffet stocks, bonds, and investors. “The everything rally is behind us,” says Saira Malik, chief investment officer of global equities at Nuveen. “It’s not going to be a sharply rising economic tide that lifts all boats from here.”</p>\n<p>That’s the general consensus among the six market strategists and chief investment officers whom<i>Barron’s</i>recently consulted. All see the S&amp;P 500 ending the year near Thursday’s close of 4536. Their average target: 4585.</p>\n<p>Next year’s gains look muted, as well, relative to recent trends. The group expects the S&amp;P 500 to tack on another 6% in 2022, rising to about 4800.</p>\n<p><img src=\"https://static.tigerbbs.com/eb61c7b74b9b0f18a019afb4ac44ad59\" tg-width=\"300\" tg-height=\"645\" referrerpolicy=\"no-referrer\">With stocks trading for about 21 times the coming year’s expected earnings,bonds yielding little, and cash yielding less than nothing after accounting for inflation, investors face tough asset-allocation decisions. In place of the “everything rally,” which lifted fast-growing tech stocks, no-growth meme stocks, and the Dogecoins of the digital world, our market watchers recommend focusing on “quality” investments. In equities, that means shares of businesses with solid balance sheets, expanding profit margins, and ample and recurring free cash flow. Even if the averages do little in coming months, these stocks are likely to shine.</p>\n<p>The stock market’s massive rally in the past year was a gift of sorts from the Federal Reserve, which flooded the financial system with money to stave off theeconomic damage wrought by the Covid pandemic. Since March 2020, the U.S. central bank has been buying a combined $120 billion a month of U.S. Treasuries and mortgage-backed securities, while keeping its benchmark federal-funds rate target at 0% to 0.25%. These moves have depressed bond yields and pushed investors into riskier assets, including stocks.</p>\n<p>Fed Chairman Jerome <a href=\"https://laohu8.com/S/POWL\">Powell</a> has said that the central bank might begin to wind down, or taper, its emergency asset purchases sometime in the coming quarters, a move that could roil risk assets of all sorts. “For us, it’s very simple: Tapering is tightening,” says Mike Wilson, chief investment officer and chief U.S. equity strategist atMorgan Stanley.“It’s the first step away from maximum accommodation [by the Fed]. They’re being very calculated about it this time, but the bottom line is that it should have a negative effect on equity valuations.”</p>\n<p>The government’s stimulus spending, too, has peaked, the strategists note. Supplemental federal unemployment benefits of $300 a week expire as of Sept. 6. Although Congress seems likely to pass a bipartisan infrastructure bill this fall, the near-term economic impact will pale in comparison to the multiple rounds of stimulus introduced since March 2020.</p>\n<p><img src=\"https://static.tigerbbs.com/c2cb76c498c1c4c980139e3d0514c261\" tg-width=\"300\" tg-height=\"645\" referrerpolicy=\"no-referrer\">The bill includes about $550 billion in new spending—a fraction of the trillions authorized by previous laws—and it will be spread out over many years. The short-term boost that infrastructure stimulus will give to consumer spending, which accounts for almost 70% of U.S. growth domestic product, won’t come close to what the economy saw after millions of Americans received checks from the government this past year.</p>\n<p>A budget bill approved by Democrats only should follow the infrastructure bill, and include spending to support Medicare expansion, child-care funding, free community-college tuition, public housing, and climate-related measures, among other party priorities. Congress could vote to lift taxes on corporations and high-earning individuals to offset that spending—another near-term risk to the market.</p>\n<p><img src=\"https://static.tigerbbs.com/6693da658db16059fc99e08a7531675f\" tg-width=\"300\" tg-height=\"645\" referrerpolicy=\"no-referrer\">Other politically charged issues likewise could derail equities this fall. Congress needs to pass a debt-ceiling increase to fund the government, and a stop-gap spending bill later this month to avoid a <a href=\"https://laohu8.com/S/WASH\">Washington</a> shutdown in October.</p>\n<p>For now, our market experts are relatively sanguine about the economic impact of the Delta variant of Covid-19. As long as vaccines remain effective in minimizing severe infections that lead to hospitalizations and deaths, the negative effects of the current Covid wave will be limited largely to the travel industry and movie theaters, they say. Wall Street’s base case for the market doesn’t include a renewed wave of lockdowns that would undermine economic growth.</p>\n<p>Inflation has been a hot topic at the Fed and among investors, partly because it has been running so hot of late. The U.S. consumer price index rose at an annualized 5.4% in both June and July—a spike the Fed calls transitory, although others aren’t so sure. The strategists are taking Powell’s side of the argument; they expect inflation to fall significantly next year. Their forecasts fall between 2.5% and 3.5%, which they consider manageable for consumers and companies, and an acceptable side effect of rapid economic growth. An inflation rate above 2.5%, however, combined with Fed tapering, would mean that now ultralow bond yields should rise.</p>\n<p>“We think inflation will continue to run hotter than it has since the financial crisis, but it’s hard for us to see inflation much over 2.5% once many of the reopening-related pressures start to dissipate,” says Michael Fredericks, head of income investing for theBlackRockMulti-Asset Strategies Group. “So bond yields do need to move up, but that will happen gradually.”</p>\n<p>The strategists see the yield on the 10-year U.S. Treasury note climbing to around 1.65% by year end. That’s about 35 basis points—or hundredths of a percentage point—above current levels, but below the 1.75% that the yield reached at its March 2021 highs. By next year, the 10-year Treasury could yield 2%, the group says. Those aren’t big moves in absolute terms, but they’re meaningful for&nbsp;the bond market—and could be even more so for stocks.</p>\n<p>Rising yields tend to weigh on stock valuations for two reasons. Higher-yielding bonds offer competition to stocks, and companies’ future earnings are worthless in the present when discounting them at a higher rate. Still, a 10-year yield around 2% won’t be enough to knock stock valuations down to pre-Covid levels. Even if yields climb, market strategists see the price/earnings multiple of the S&amp;P 500 holding well above its 30-year average of 16 times forward earnings. The index’s forward P/E topped 23 last fall.</p>\n<p><img src=\"https://static.tigerbbs.com/e08d24cb421d7cc13debd76a9c6fea01\" tg-width=\"660\" tg-height=\"434\" referrerpolicy=\"no-referrer\"></p>\n<p>As long as 10-year Treasury yields stay in the 2% range, the S&amp;P 500 should be able to command a forward P/E in the high teens, strategists say. A return to the 16-times long-term average isn’t in the cards until there is more pressure from much higher yields—or something else that causes stocks to fall.</p>\n<p>If yields surge past 2% or 2.25%, investors could start to question equity valuations more seriously, says&nbsp;<a href=\"https://laohu8.com/S/STT\">State</a> Street’schief portfolio strategist, Gaurav Mallik: “We haven’t seen [the 10-year yield] above 2% for some time now, so that’s an important sentiment level for investors.”</p>\n<p><img src=\"https://static.tigerbbs.com/93ff6490069ab5dc1b4057f1ff7966f3\" tg-width=\"664\" tg-height=\"441\" referrerpolicy=\"no-referrer\"></p>\n<p>Wilson is more concerned, noting that the stock market’s valuation risk is asymmetric: “It’s very unlikely that multiples are going to go up, and there’s a good chance that they go down more than 10% given the deceleration in growth and where we are in the cycle,” he says</p>\n<p>If 16 to 23 times forward earnings is the range, he adds, “you’re already at the very high end of that. There’s more potential risk than reward.”</p>\n<p>Some P/E-multiple compression is baked into all six strategists’ forecasts, heaping greater importance on the path of profit growth. On average, the strategists expect S&amp;P 500 earnings to jump 46% this year, to about $204, after last year’s earnings depression. That could be followed by a more normalized gain of 9% in 2022, to about $222.50.</p>\n<p>A potential headwind would be a higher federal corporate-tax rate in 2022. The details of Democrats’ spending and taxation plans will be worked out in the coming weeks, and investors can expect to hear a lot more about potential tax increases. Several strategists see a 25% federal rate on corporate profits as a likely compromise figure, above the 21% in place since 2018, but below the 28% sought by the Biden administration.</p>\n<p>An increase of that magnitude would shave about 5% off S&amp;P 500 earnings next year. The index could drop by a similar amount as the passage of the Democrats’ reconciliation bill nears this fall, but the impact should be limited to that initial correction. As with the tax cuts in December 2017, the change should be a <a href=\"https://laohu8.com/S/AONE.U\">one</a>-time event for the market, some strategists predict.</p>\n<p>These concerns aside, investors shouldn’t miss the bigger picture: The U.S. economy is in good shape and growing robustly. The strategists expect gross domestic product to rise 6.3% this year and about 4% in 2022. “The cyclical uplift and above-trend growth will continue at least through 2022, and we want to be biased toward assets that have that exposure,” says Mallik.</p>\n<blockquote>\n “We’re going to have a hot economy this year and next. When GDP growth is above average, value beats growth and cyclicals beat defensives.”— Lori Calvasina, RBC Capital Markets\n</blockquote>\n<p>The State Street strategist recommends overweighting materials, financials, and technology in investment portfolios. That approach includes both economically sensitive companies, such as banks and miners, and steady growers in the tech sector.</p>\n<p>RBC Capital Markets’ head of U.S. equity strategy, Lori Calvasina, likewise takes a barbell approach, with both cyclical and growth exposure. Her preferred sectors are energy, financials, and technology.</p>\n<p>“Valuations are still a lot more attractive in financials and energy than growth [sectors such as technology or consumer discretionary,]” Calvasina says. “The catalyst in the near term is getting out of the current Covid wave... We’re going to have a hot economy this year and next, and traditionally when GDP growth is above average, value beats growth and cyclicals beat defensives.”</p>\n<p>But the focus on quality will be pivotal, especially moving into the second half of 2022. That’s when the Fed is likely to hike interest rates for the first time in this cycle. By 2023, the economy could return to pre-Covid growth on the order of 2%.</p>\n<p>“The historical playbook is that coming out of a recession, you tend to see low-quality outperformance that lasts about a year, then leadership flips back to high quality,” Calvasina says. “But that transition from low quality back to high quality tends to be very bumpy.”</p>\n<p><b>A Shopping List for Fall</b></p>\n<p>Most strategists favor a combination of economically sensitive stocks and steady growers, including tech shares. Financials should do well, particularly if bond yields rise.</p>\n<p><img src=\"https://static.tigerbbs.com/a54c4bd114c1a5f7f700d1fc14d30d8e\" tg-width=\"970\" tg-height=\"230\" referrerpolicy=\"no-referrer\"></p>\n<p>Although stocks with quality attributes have outperformed the market this summer, according to a <a href=\"https://laohu8.com/S/BLK\">BlackRock</a> analysis, the quality factor has lagged since positive vaccine news was first reported last November.</p>\n<p>“We’re moving into a mid-cycle environment, when underlying economic growth remains strong but momentum begins to decelerate,” BlackRock’s Fredericks says. “Our research shows that quality stocks perform particularly well in such a period.”</p>\n<p>He recommends overweighting profitable technology companies; financials, including banks, and consumer staples and industrials with those quality characteristics.</p>\n<p>For <a href=\"https://laohu8.com/S/WFC\">Wells Fargo</a>’s head of equity strategy, Christopher Harvey, a mix of post-pandemic beneficiaries and defensive exposure is the way to go. He constructed a basket of stocks with lower-than-average volatility—which should outperform during periods of market uncertainty or stress this fall—and high “Covid beta,” or sensitivity to good or bad news about the pandemic. One requirement; The stocks had to be rated the equivalent of Buy by Wells Fargo’s equity analysts.</p>\n<p>“There’s near-term economic uncertainty, interest-rate uncertainty, and Covid risk, and generally we’re in a seasonally weaker part of the year around September,” says Harvey. “If we can balance low vol and high Covid beta, we can mitigate a lot of the upcoming uncertainty and volatility around timing of several of those catalysts. Longer-term, though, we still want to have that [reopening exposure.]”</p>\n<p>Harvey’s list of low-volatility stocks with high Covid beta includesApple(AAPL),<a href=\"https://laohu8.com/S/BAC\">Bank of America</a>(BAC),<a href=\"https://laohu8.com/S/NTRSP\">Northern</a> Trust(NTRS),Lowe’s(LOW),<a href=\"https://laohu8.com/S/IQV\">IQVIA</a> Holdings(IQV), andMasco(MAS).</p>\n<p>Overall, banks are the most frequently recommended group for the months ahead. TheInvesco KBW Bankexchange-traded fund (KBWB) provides broad exposure to the sector in the U.S.</p>\n<p>“We like the valuations [and] credit quality; they are now allowed to buy back shares and increase dividends, and there’s higher Covid beta,” says Harvey.</p>\n<p>Cheaper valuations mean less potential downside in a market correction. And, contrary to much of the rest of the stock market, higher interest rates would be a tailwind for the banks, which could then charge more for loans.</p>\n<p><a href=\"https://laohu8.com/S/HCSG\">Healthcare</a> stocks also have some fans. “<a href=\"https://laohu8.com/S/HR\">Healthcare</a> has both defensive and growth attributes to it,” Wilson says. “You’re paying a lot less per unit of growth in healthcare today than you are in other sectors. So we think it provides good balance in this market when we’re worried about valuation.” Health insurerHumana(HUM) makes Wilson’s “Fresh Money Buy List” of stocks Buy-rated by <a href=\"https://laohu8.com/S/MS\">Morgan Stanley</a> analysts and fitting his macro views.</p>\n<p>Nuveen’s Malik is also looking toward health care for relatively underpriced growth exposure, namely in the pharmaceuticals and biotechnology groups. She points toSeagen(SGEN), which is focused on oncology drugs and could be an attractive acquisition target for a pharma giant.</p>\n<p>Malik also likesAbbVie(ABBV) which trades at an undemanding eight times forward earnings and sports a 4.7% dividend yield. The coming expiration of patents on its blockbuster anti-inflammatory drug Humira has kept some investors away, but Malik is confident that management can limit the damage and sees promising drugs in development at the $200 billion company.</p>\n<p>Both stocks have had a tough time in recent days. Seagen fell more than 8% last week, to around $152, on news that its co-founder and CEO sold a large number of shares recently. AndAbbVietanked 7% Wednesday, to $112.27, after the Food and Drug Administration required new warning labels for JAK inhibitors, a type of anti-rheumatoid drug that includes one of <a href=\"https://laohu8.com/S/ABBV\">AbbVie</a>’s most promising post-Humira products.</p>\n<p><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>(PFE),<a href=\"https://laohu8.com/S/AXP\">American Express</a>(AXP),Johnson &amp; Johnson(JNJ), andCisco Systems(CSCO) are other S&amp;P 500 members that pass a<i>Barron’s</i>screen for quality attributes.</p>\n<p>After a year of steady gains, investors might be reminded this fall that stocks can also decline, as growth momentum and policy support begin to fade. But underlying economic strength supports buying the dip, should the market drop from its highs. <a href=\"https://laohu8.com/S/JE\">Just</a> be more selective. And go with quality.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Strategists Say the Stock Market Could Struggle This Fall. What to Buy Now?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStrategists Say the Stock Market Could Struggle This Fall. What to Buy Now?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-07 17:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/stocks-could-struggle-this-fall-market-strategists-say-stick-with-quality-companies-51630699840?siteid=yhoof2><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What a year this has been for the markets! Fueled by a torrent of monetary and fiscal stimulus, economic and earnings growth, and (until recently) a mostly receding pandemic, theS&P 500stock index has...</p>\n\n<a href=\"https://www.barrons.com/articles/stocks-could-struggle-this-fall-market-strategists-say-stick-with-quality-companies-51630699840?siteid=yhoof2\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite","SPY":"标普500ETF",".SPX":"S&P 500 Index"},"source_url":"https://www.barrons.com/articles/stocks-could-struggle-this-fall-market-strategists-say-stick-with-quality-companies-51630699840?siteid=yhoof2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130130857","content_text":"What a year this has been for the markets! Fueled by a torrent of monetary and fiscal stimulus, economic and earnings growth, and (until recently) a mostly receding pandemic, theS&P 500stock index has rallied 20%, notching seven straight months of gains and more than 50 highs along the way. And that’s on top of last year’s 68% rebound from the market’s March 2020 lows.\nTailwinds remain in place, but headwinds now loom that could slow stocks’ advance. Stimulus spending has peaked, and economic and corporate-earnings growth are likely to decelerate through the end of the year. What’s more, theFederal Reserve has all but promised to start tapering its bond buyingin coming months, and the Biden administration has proposed hiking corporate and personal tax rates. None of this is apt to sit well with holders of increasingly pricey shares.\nIn other words,brace for a volatile fallin which conflicting forces buffet stocks, bonds, and investors. “The everything rally is behind us,” says Saira Malik, chief investment officer of global equities at Nuveen. “It’s not going to be a sharply rising economic tide that lifts all boats from here.”\nThat’s the general consensus among the six market strategists and chief investment officers whomBarron’srecently consulted. All see the S&P 500 ending the year near Thursday’s close of 4536. Their average target: 4585.\nNext year’s gains look muted, as well, relative to recent trends. The group expects the S&P 500 to tack on another 6% in 2022, rising to about 4800.\nWith stocks trading for about 21 times the coming year’s expected earnings,bonds yielding little, and cash yielding less than nothing after accounting for inflation, investors face tough asset-allocation decisions. In place of the “everything rally,” which lifted fast-growing tech stocks, no-growth meme stocks, and the Dogecoins of the digital world, our market watchers recommend focusing on “quality” investments. In equities, that means shares of businesses with solid balance sheets, expanding profit margins, and ample and recurring free cash flow. Even if the averages do little in coming months, these stocks are likely to shine.\nThe stock market’s massive rally in the past year was a gift of sorts from the Federal Reserve, which flooded the financial system with money to stave off theeconomic damage wrought by the Covid pandemic. Since March 2020, the U.S. central bank has been buying a combined $120 billion a month of U.S. Treasuries and mortgage-backed securities, while keeping its benchmark federal-funds rate target at 0% to 0.25%. These moves have depressed bond yields and pushed investors into riskier assets, including stocks.\nFed Chairman Jerome Powell has said that the central bank might begin to wind down, or taper, its emergency asset purchases sometime in the coming quarters, a move that could roil risk assets of all sorts. “For us, it’s very simple: Tapering is tightening,” says Mike Wilson, chief investment officer and chief U.S. equity strategist atMorgan Stanley.“It’s the first step away from maximum accommodation [by the Fed]. They’re being very calculated about it this time, but the bottom line is that it should have a negative effect on equity valuations.”\nThe government’s stimulus spending, too, has peaked, the strategists note. Supplemental federal unemployment benefits of $300 a week expire as of Sept. 6. Although Congress seems likely to pass a bipartisan infrastructure bill this fall, the near-term economic impact will pale in comparison to the multiple rounds of stimulus introduced since March 2020.\nThe bill includes about $550 billion in new spending—a fraction of the trillions authorized by previous laws—and it will be spread out over many years. The short-term boost that infrastructure stimulus will give to consumer spending, which accounts for almost 70% of U.S. growth domestic product, won’t come close to what the economy saw after millions of Americans received checks from the government this past year.\nA budget bill approved by Democrats only should follow the infrastructure bill, and include spending to support Medicare expansion, child-care funding, free community-college tuition, public housing, and climate-related measures, among other party priorities. Congress could vote to lift taxes on corporations and high-earning individuals to offset that spending—another near-term risk to the market.\nOther politically charged issues likewise could derail equities this fall. Congress needs to pass a debt-ceiling increase to fund the government, and a stop-gap spending bill later this month to avoid a Washington shutdown in October.\nFor now, our market experts are relatively sanguine about the economic impact of the Delta variant of Covid-19. As long as vaccines remain effective in minimizing severe infections that lead to hospitalizations and deaths, the negative effects of the current Covid wave will be limited largely to the travel industry and movie theaters, they say. Wall Street’s base case for the market doesn’t include a renewed wave of lockdowns that would undermine economic growth.\nInflation has been a hot topic at the Fed and among investors, partly because it has been running so hot of late. The U.S. consumer price index rose at an annualized 5.4% in both June and July—a spike the Fed calls transitory, although others aren’t so sure. The strategists are taking Powell’s side of the argument; they expect inflation to fall significantly next year. Their forecasts fall between 2.5% and 3.5%, which they consider manageable for consumers and companies, and an acceptable side effect of rapid economic growth. An inflation rate above 2.5%, however, combined with Fed tapering, would mean that now ultralow bond yields should rise.\n“We think inflation will continue to run hotter than it has since the financial crisis, but it’s hard for us to see inflation much over 2.5% once many of the reopening-related pressures start to dissipate,” says Michael Fredericks, head of income investing for theBlackRockMulti-Asset Strategies Group. “So bond yields do need to move up, but that will happen gradually.”\nThe strategists see the yield on the 10-year U.S. Treasury note climbing to around 1.65% by year end. That’s about 35 basis points—or hundredths of a percentage point—above current levels, but below the 1.75% that the yield reached at its March 2021 highs. By next year, the 10-year Treasury could yield 2%, the group says. Those aren’t big moves in absolute terms, but they’re meaningful for the bond market—and could be even more so for stocks.\nRising yields tend to weigh on stock valuations for two reasons. Higher-yielding bonds offer competition to stocks, and companies’ future earnings are worthless in the present when discounting them at a higher rate. Still, a 10-year yield around 2% won’t be enough to knock stock valuations down to pre-Covid levels. Even if yields climb, market strategists see the price/earnings multiple of the S&P 500 holding well above its 30-year average of 16 times forward earnings. The index’s forward P/E topped 23 last fall.\n\nAs long as 10-year Treasury yields stay in the 2% range, the S&P 500 should be able to command a forward P/E in the high teens, strategists say. A return to the 16-times long-term average isn’t in the cards until there is more pressure from much higher yields—or something else that causes stocks to fall.\nIf yields surge past 2% or 2.25%, investors could start to question equity valuations more seriously, says State Street’schief portfolio strategist, Gaurav Mallik: “We haven’t seen [the 10-year yield] above 2% for some time now, so that’s an important sentiment level for investors.”\n\nWilson is more concerned, noting that the stock market’s valuation risk is asymmetric: “It’s very unlikely that multiples are going to go up, and there’s a good chance that they go down more than 10% given the deceleration in growth and where we are in the cycle,” he says\nIf 16 to 23 times forward earnings is the range, he adds, “you’re already at the very high end of that. There’s more potential risk than reward.”\nSome P/E-multiple compression is baked into all six strategists’ forecasts, heaping greater importance on the path of profit growth. On average, the strategists expect S&P 500 earnings to jump 46% this year, to about $204, after last year’s earnings depression. That could be followed by a more normalized gain of 9% in 2022, to about $222.50.\nA potential headwind would be a higher federal corporate-tax rate in 2022. The details of Democrats’ spending and taxation plans will be worked out in the coming weeks, and investors can expect to hear a lot more about potential tax increases. Several strategists see a 25% federal rate on corporate profits as a likely compromise figure, above the 21% in place since 2018, but below the 28% sought by the Biden administration.\nAn increase of that magnitude would shave about 5% off S&P 500 earnings next year. The index could drop by a similar amount as the passage of the Democrats’ reconciliation bill nears this fall, but the impact should be limited to that initial correction. As with the tax cuts in December 2017, the change should be a one-time event for the market, some strategists predict.\nThese concerns aside, investors shouldn’t miss the bigger picture: The U.S. economy is in good shape and growing robustly. The strategists expect gross domestic product to rise 6.3% this year and about 4% in 2022. “The cyclical uplift and above-trend growth will continue at least through 2022, and we want to be biased toward assets that have that exposure,” says Mallik.\n\n “We’re going to have a hot economy this year and next. When GDP growth is above average, value beats growth and cyclicals beat defensives.”— Lori Calvasina, RBC Capital Markets\n\nThe State Street strategist recommends overweighting materials, financials, and technology in investment portfolios. That approach includes both economically sensitive companies, such as banks and miners, and steady growers in the tech sector.\nRBC Capital Markets’ head of U.S. equity strategy, Lori Calvasina, likewise takes a barbell approach, with both cyclical and growth exposure. Her preferred sectors are energy, financials, and technology.\n“Valuations are still a lot more attractive in financials and energy than growth [sectors such as technology or consumer discretionary,]” Calvasina says. “The catalyst in the near term is getting out of the current Covid wave... We’re going to have a hot economy this year and next, and traditionally when GDP growth is above average, value beats growth and cyclicals beat defensives.”\nBut the focus on quality will be pivotal, especially moving into the second half of 2022. That’s when the Fed is likely to hike interest rates for the first time in this cycle. By 2023, the economy could return to pre-Covid growth on the order of 2%.\n“The historical playbook is that coming out of a recession, you tend to see low-quality outperformance that lasts about a year, then leadership flips back to high quality,” Calvasina says. “But that transition from low quality back to high quality tends to be very bumpy.”\nA Shopping List for Fall\nMost strategists favor a combination of economically sensitive stocks and steady growers, including tech shares. Financials should do well, particularly if bond yields rise.\n\nAlthough stocks with quality attributes have outperformed the market this summer, according to a BlackRock analysis, the quality factor has lagged since positive vaccine news was first reported last November.\n“We’re moving into a mid-cycle environment, when underlying economic growth remains strong but momentum begins to decelerate,” BlackRock’s Fredericks says. “Our research shows that quality stocks perform particularly well in such a period.”\nHe recommends overweighting profitable technology companies; financials, including banks, and consumer staples and industrials with those quality characteristics.\nFor Wells Fargo’s head of equity strategy, Christopher Harvey, a mix of post-pandemic beneficiaries and defensive exposure is the way to go. He constructed a basket of stocks with lower-than-average volatility—which should outperform during periods of market uncertainty or stress this fall—and high “Covid beta,” or sensitivity to good or bad news about the pandemic. One requirement; The stocks had to be rated the equivalent of Buy by Wells Fargo’s equity analysts.\n“There’s near-term economic uncertainty, interest-rate uncertainty, and Covid risk, and generally we’re in a seasonally weaker part of the year around September,” says Harvey. “If we can balance low vol and high Covid beta, we can mitigate a lot of the upcoming uncertainty and volatility around timing of several of those catalysts. Longer-term, though, we still want to have that [reopening exposure.]”\nHarvey’s list of low-volatility stocks with high Covid beta includesApple(AAPL),Bank of America(BAC),Northern Trust(NTRS),Lowe’s(LOW),IQVIA Holdings(IQV), andMasco(MAS).\nOverall, banks are the most frequently recommended group for the months ahead. TheInvesco KBW Bankexchange-traded fund (KBWB) provides broad exposure to the sector in the U.S.\n“We like the valuations [and] credit quality; they are now allowed to buy back shares and increase dividends, and there’s higher Covid beta,” says Harvey.\nCheaper valuations mean less potential downside in a market correction. And, contrary to much of the rest of the stock market, higher interest rates would be a tailwind for the banks, which could then charge more for loans.\nHealthcare stocks also have some fans. “Healthcare has both defensive and growth attributes to it,” Wilson says. “You’re paying a lot less per unit of growth in healthcare today than you are in other sectors. So we think it provides good balance in this market when we’re worried about valuation.” Health insurerHumana(HUM) makes Wilson’s “Fresh Money Buy List” of stocks Buy-rated by Morgan Stanley analysts and fitting his macro views.\nNuveen’s Malik is also looking toward health care for relatively underpriced growth exposure, namely in the pharmaceuticals and biotechnology groups. She points toSeagen(SGEN), which is focused on oncology drugs and could be an attractive acquisition target for a pharma giant.\nMalik also likesAbbVie(ABBV) which trades at an undemanding eight times forward earnings and sports a 4.7% dividend yield. The coming expiration of patents on its blockbuster anti-inflammatory drug Humira has kept some investors away, but Malik is confident that management can limit the damage and sees promising drugs in development at the $200 billion company.\nBoth stocks have had a tough time in recent days. Seagen fell more than 8% last week, to around $152, on news that its co-founder and CEO sold a large number of shares recently. AndAbbVietanked 7% Wednesday, to $112.27, after the Food and Drug Administration required new warning labels for JAK inhibitors, a type of anti-rheumatoid drug that includes one of AbbVie’s most promising post-Humira products.\nPfizer(PFE),American Express(AXP),Johnson & Johnson(JNJ), andCisco Systems(CSCO) are other S&P 500 members that pass aBarron’sscreen for quality attributes.\nAfter a year of steady gains, investors might be reminded this fall that stocks can also decline, as growth momentum and policy support begin to fade. But underlying economic strength supports buying the dip, should the market drop from its highs. Just be more selective. And go with quality.","news_type":1},"isVote":1,"tweetType":1,"viewCount":175,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":817165360,"gmtCreate":1630920535050,"gmtModify":1631885788150,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AP4.SI\">$RIVERSTONE HOLDINGS LIMITED(AP4.SI)$</a>&nbsp;hmmm.... If 👇&nbsp;again i ll average 👇&nbsp;","listText":"<a href=\"https://laohu8.com/S/AP4.SI\">$RIVERSTONE HOLDINGS LIMITED(AP4.SI)$</a>&nbsp;hmmm.... If 👇&nbsp;again i ll average 👇&nbsp;","text":"$RIVERSTONE HOLDINGS LIMITED(AP4.SI)$ hmmm.... If 👇 again i ll average 👇","images":[{"img":"https://static.tigerbbs.com/b7ce034ea1f1dd6a03ce00365ca929b1","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/817165360","isVote":1,"tweetType":1,"viewCount":485,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":817166739,"gmtCreate":1630920332921,"gmtModify":1631887920368,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ME8U.SI\">$MAPLETREE INDUSTRIAL TRUST(ME8U.SI)$</a>🤑","listText":"<a href=\"https://laohu8.com/S/ME8U.SI\">$MAPLETREE INDUSTRIAL TRUST(ME8U.SI)$</a>🤑","text":"$MAPLETREE INDUSTRIAL TRUST(ME8U.SI)$🤑","images":[{"img":"https://static.tigerbbs.com/c4d3fadb9d9dc8ae8804d10ac4f6904e","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/817166739","isVote":1,"tweetType":1,"viewCount":363,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":815268068,"gmtCreate":1630681235854,"gmtModify":1632467193337,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"Not sure is it&nbsp;good price to enter, but just do it💪💪","listText":"Not sure is it&nbsp;good price to enter, but just do it💪💪","text":"Not sure is it good price to enter, but just do it💪💪","images":[{"img":"https://static.tigerbbs.com/c36c1c4fa06c4203edd1ee21ea207bc7","width":"1080","height":"3192"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/815268068","isVote":1,"tweetType":1,"viewCount":276,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":815269105,"gmtCreate":1630681104507,"gmtModify":1632467217325,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/815269105","repostId":"1198573200","repostType":4,"isVote":1,"tweetType":1,"viewCount":142,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":815260728,"gmtCreate":1630681069064,"gmtModify":1632467220336,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"Tgif","listText":"Tgif","text":"Tgif","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/815260728","repostId":"2164879370","repostType":4,"repost":{"id":"2164879370","kind":"highlight","pubTimestamp":1630678680,"share":"https://www.laohu8.com/m/news/2164879370?lang=&edition=full","pubTime":"2021-09-03 22:18","market":"us","language":"en","title":"3 Hypergrowth Stocks Expected to Increase Sales 1,185% to 12,629% by 2023","url":"https://stock-news.laohu8.com/highlight/detail?id=2164879370","media":"Motley Fool","summary":"These fast-paced companies should generate jaw-dropping revenue growth over the next three years.","content":"<p>Since the end of the Great Recession in 2009, growth stocks have thrived. Historically low lending rates, an ongoing quantitative easing program designed to weigh down long-term bond yields, and a free-spending Congress have all helped to make cheap capital widely abundant for businesses. This is helping to fuel acquisitions, hiring, and (most importantly) innovation.</p>\n<p>Yet for some companies, their exponential growth is just beginning. For each of the following hypergrowth stocks, Wall Street's consensus sales estimate for 2023, courtesy of <b>FactSet</b>, implies a revenue increase ranging from a low of 1,185% (yes, <i>a low of 1,185%</i>) to a high of 12,629%, compared to 2020 sales.</p>\n<h2>Moderna: Implied sales increase of 1,185%</h2>\n<p>Arguably the best-known name on this list is biotech <b>Moderna</b> (NASDAQ:MRNA). According to Wall Street, Moderna's annual revenue is expected to catapult from the $803.4 million recorded in 2020 to an estimated $10.33 billion in 2023. Interestingly, the $10.33 billion in projected sales for 2023 is about half of the $20.13 billion forecast this year.</p>\n<p>As a lot of you probably know, Modena's success is tied to the development of its coronavirus vaccine mRNA-1273. When the company ran a large-scale study of its COVID-19 vaccine, the results (released in November) demonstrated a vaccine efficacy (VE) of 94% and a strong propensity to keep vaccinated individuals from getting severe forms of the disease. This initial VE made Moderna's COVID vaccine a slam dunk for Emergency Use Authorization in the United States.</p>\n<p>When the company announced its second-quarter operating results on Aug. 5, it stuck to its original forecast of delivering between 800 million and 1 billion doses in 2021, with net product sales of around $20 billion. Next year, Moderna believes it can provide between 2 billion and 3 billion doses. As a reminder, the Moderna vaccine is a two-dose regimen, meaning its 2022 output could fully inoculate 1 billion to 1.5 billion people.</p>\n<p>Also working in Modena's favor is the possibility of booster vaccinations. The mutability of COVID, coupled with a handful of studies suggesting that VE begins waning at the six-month mark, could create a recurring vaccination need globally.</p>\n<p>While Moderna might sound like a surefire growth story, there are still big question marks about its future. For example, even though mRNA-1273 has been wildly successful, it's the only therapy that's generating sales for the company. Moderna's non-COVID pipeline looks to be years away from bringing in meaningful revenue.</p>\n<p>Equally concerning is the likelihood that the COVID vaccine space is going to become crowded. At some point soon, <b>Novavax</b>&nbsp;should join the field with a formidable initial VE of about 90%. It is also working on a combination COVID/influenza vaccine, which would be a differentiator and game changer.</p>\n<p>Not to take anything away from what Moderna has done, but a $150 billion market cap for a company with a single therapy seems awfully risky.</p>\n<h2><a href=\"https://laohu8.com/S/ZGNX\">Zogenix</a>: Implied sales increase of 2,451%</h2>\n<p>Another biotech stock that's expected to generate jaw-dropping sales growth through 2023 is small-cap <b>Zogenix</b> (NASDAQ:ZGNX). If Wall Street's consensus estimate proves accurate, the company's $13.64 million in reported sales in 2020 could grow to $348 million by 2023.</p>\n<p>Like Moderna, there's a single drug that looks to do all of the heavy lifting for Zogenix over the next couple of years: Fintepla. This is a drug targeted at a variety of seizure-related indications. It's already been approved by the Food and Drug Administration to treat Dravet syndrome. And Zogenix has plans to file a supplemental new drug application by the end of the current quarter to expand Fintepla's label to include Lennox-Gastaut syndrome (LGS). Both Dravet and LGS are rare forms of childhood-onset epilepsy. If approved, Zogenix could launch Fintepla for LGS patients in this country by as early as the first half of 2022.</p>\n<p>And Zogenix still isn't done with Fintepla. After hashing out the finer points with the FDA, the company intends to initiate a phase 3 study involving Fintepla as a treatment for CDKL5 deficiency disorder before the end of the year. Thus, organic growth and label expansion opportunities are expected to fuel sales of Fintepla to almost $350 million in three years.</p>\n<p>What'll be particularly interesting is how Zogenix fares against cannabinoid-focused drug developer GW Pharmaceuticals, which was acquired by <b>Jazz Pharmaceuticals</b> (NASDAQ:JAZZ) in May. GW's lead drug, Epidiolex, is a cannabidiol-based treatment that's been approved by the FDA to treat Dravet syndrome and LGS, and it launched in advance of Zogenix's Fintepla. For comparative purposes, Jazz announced that Epidiolex brought home $155.9 million in sales just in the second quarter, although it has an additional indication under its belt (tuberous sclerosis complex) where it won't compete against Zogenix.</p>\n<p>Although Epidiolex appears to have the upper hand now, it's worth noting that seizure-reduction efficacy for Fintepla looked very promising in late-stage clinical trials. To be 100% clear, the GW Pharma and Zogenix studies were never pitted head-to-head, and their baseline parameters are different. Nevertheless, Fintepla led to a 62.3% reduction in mean monthly convulsive seizure frequency compared to placebo at the six-week mark for Dravet syndrome patients.</p>\n<p>Comparatively, Jazz's Epidiolex demonstrated reductions in seizure frequency from baseline of 56% and 47%, respectively, for the lower- and higher-dose treatments in phase 3 studies in Dravet syndrome patients.&nbsp; Suffice it to say, these could be highly competitive indications for the foreseeable future.</p>\n<h2>Marathon Digital Holdings: Implied sales increase of 12,629%</h2>\n<p>Now, if you want pedal-to-the-metal growth, look no further than <b>Marathon Digital Holdings</b> (NASDAQ:MARA). After reporting a meager $4.36 million in sales in 2020, Wall Street anticipates full-year sales will climb to $555 million by 2023. That's an increase of 12,629%.</p>\n<p>If you're wondering how sales growth of this magnitude is possible for a company not involved in drug development, look no further than cryptocurrencies.</p>\n<p>Marathon Digital is a cryptocurrency mining company. It operates a farm of high-powered computing devices designed to solve complex mathematical equations that validate groups of transactions (known as a block) as valid on a digital currency's blockchain. For being the first to validate a block, Marathon is paid a block reward. This reward is typically a set amount of digital tokens from the digital currency being mined.</p>\n<p>In Marathon's case, it's mining <b>Bitcoin</b> (CRYPTO:BTC), the largest cryptocurrency in the world by market cap. Being the first to mine a Bitcoin block results in the company being awarded 6.25 Bitcoin tokens, which were worth a cool $292,000, as of Aug. 30.</p>\n<p>The reason Marathon's sales are skyrocketing so quickly is because it's in the midst of deploying <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the largest Bitcoin-mining operations in the United States. As of the beginning of August, approximately 30,100 miners were operating, with another 103,000 ordered and yet to be installed. By the end of the first quarter of 2022, Marathon should have north of 100,000 miners in operation, with all 133,120 up and running by July 2022.</p>\n<p>Though Marathon is the fastest-growing of these three hypergrowth stocks, it's also arguably the most dangerous investment of this trio. That's because it's entirely dependent on external factors, such as interest in, and the price of, Bitcoin -- and not innovation.</p>\n<p>What's more, the barrier to entry in the cryptocurrency mining space is virtually nonexistent. As time passes, it's going to be tougher for Marathon to successfully mine Bitcoin.</p>\n<p>As the icing on the cake, Bitcoin's block rewards halve every four years. By 2024, only 3.125 Bitcoin tokens will be paid for validating a block. Essentially, Marathon is competing against a growing number of mining companies for a reward that's shrinking. It simply doesn't sound like an operating model with long-term staying power.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Hypergrowth Stocks Expected to Increase Sales 1,185% to 12,629% by 2023</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Hypergrowth Stocks Expected to Increase Sales 1,185% to 12,629% by 2023\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-03 22:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/03/3-hypergrowth-stocks-increase-sales-1185-to-12629/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Since the end of the Great Recession in 2009, growth stocks have thrived. Historically low lending rates, an ongoing quantitative easing program designed to weigh down long-term bond yields, and a ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/03/3-hypergrowth-stocks-increase-sales-1185-to-12629/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","ZGNX":"Zogenix","MARA":"Marathon Digital Holdings Inc"},"source_url":"https://www.fool.com/investing/2021/09/03/3-hypergrowth-stocks-increase-sales-1185-to-12629/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2164879370","content_text":"Since the end of the Great Recession in 2009, growth stocks have thrived. Historically low lending rates, an ongoing quantitative easing program designed to weigh down long-term bond yields, and a free-spending Congress have all helped to make cheap capital widely abundant for businesses. This is helping to fuel acquisitions, hiring, and (most importantly) innovation.\nYet for some companies, their exponential growth is just beginning. For each of the following hypergrowth stocks, Wall Street's consensus sales estimate for 2023, courtesy of FactSet, implies a revenue increase ranging from a low of 1,185% (yes, a low of 1,185%) to a high of 12,629%, compared to 2020 sales.\nModerna: Implied sales increase of 1,185%\nArguably the best-known name on this list is biotech Moderna (NASDAQ:MRNA). According to Wall Street, Moderna's annual revenue is expected to catapult from the $803.4 million recorded in 2020 to an estimated $10.33 billion in 2023. Interestingly, the $10.33 billion in projected sales for 2023 is about half of the $20.13 billion forecast this year.\nAs a lot of you probably know, Modena's success is tied to the development of its coronavirus vaccine mRNA-1273. When the company ran a large-scale study of its COVID-19 vaccine, the results (released in November) demonstrated a vaccine efficacy (VE) of 94% and a strong propensity to keep vaccinated individuals from getting severe forms of the disease. This initial VE made Moderna's COVID vaccine a slam dunk for Emergency Use Authorization in the United States.\nWhen the company announced its second-quarter operating results on Aug. 5, it stuck to its original forecast of delivering between 800 million and 1 billion doses in 2021, with net product sales of around $20 billion. Next year, Moderna believes it can provide between 2 billion and 3 billion doses. As a reminder, the Moderna vaccine is a two-dose regimen, meaning its 2022 output could fully inoculate 1 billion to 1.5 billion people.\nAlso working in Modena's favor is the possibility of booster vaccinations. The mutability of COVID, coupled with a handful of studies suggesting that VE begins waning at the six-month mark, could create a recurring vaccination need globally.\nWhile Moderna might sound like a surefire growth story, there are still big question marks about its future. For example, even though mRNA-1273 has been wildly successful, it's the only therapy that's generating sales for the company. Moderna's non-COVID pipeline looks to be years away from bringing in meaningful revenue.\nEqually concerning is the likelihood that the COVID vaccine space is going to become crowded. At some point soon, Novavax should join the field with a formidable initial VE of about 90%. It is also working on a combination COVID/influenza vaccine, which would be a differentiator and game changer.\nNot to take anything away from what Moderna has done, but a $150 billion market cap for a company with a single therapy seems awfully risky.\nZogenix: Implied sales increase of 2,451%\nAnother biotech stock that's expected to generate jaw-dropping sales growth through 2023 is small-cap Zogenix (NASDAQ:ZGNX). If Wall Street's consensus estimate proves accurate, the company's $13.64 million in reported sales in 2020 could grow to $348 million by 2023.\nLike Moderna, there's a single drug that looks to do all of the heavy lifting for Zogenix over the next couple of years: Fintepla. This is a drug targeted at a variety of seizure-related indications. It's already been approved by the Food and Drug Administration to treat Dravet syndrome. And Zogenix has plans to file a supplemental new drug application by the end of the current quarter to expand Fintepla's label to include Lennox-Gastaut syndrome (LGS). Both Dravet and LGS are rare forms of childhood-onset epilepsy. If approved, Zogenix could launch Fintepla for LGS patients in this country by as early as the first half of 2022.\nAnd Zogenix still isn't done with Fintepla. After hashing out the finer points with the FDA, the company intends to initiate a phase 3 study involving Fintepla as a treatment for CDKL5 deficiency disorder before the end of the year. Thus, organic growth and label expansion opportunities are expected to fuel sales of Fintepla to almost $350 million in three years.\nWhat'll be particularly interesting is how Zogenix fares against cannabinoid-focused drug developer GW Pharmaceuticals, which was acquired by Jazz Pharmaceuticals (NASDAQ:JAZZ) in May. GW's lead drug, Epidiolex, is a cannabidiol-based treatment that's been approved by the FDA to treat Dravet syndrome and LGS, and it launched in advance of Zogenix's Fintepla. For comparative purposes, Jazz announced that Epidiolex brought home $155.9 million in sales just in the second quarter, although it has an additional indication under its belt (tuberous sclerosis complex) where it won't compete against Zogenix.\nAlthough Epidiolex appears to have the upper hand now, it's worth noting that seizure-reduction efficacy for Fintepla looked very promising in late-stage clinical trials. To be 100% clear, the GW Pharma and Zogenix studies were never pitted head-to-head, and their baseline parameters are different. Nevertheless, Fintepla led to a 62.3% reduction in mean monthly convulsive seizure frequency compared to placebo at the six-week mark for Dravet syndrome patients.\nComparatively, Jazz's Epidiolex demonstrated reductions in seizure frequency from baseline of 56% and 47%, respectively, for the lower- and higher-dose treatments in phase 3 studies in Dravet syndrome patients.  Suffice it to say, these could be highly competitive indications for the foreseeable future.\nMarathon Digital Holdings: Implied sales increase of 12,629%\nNow, if you want pedal-to-the-metal growth, look no further than Marathon Digital Holdings (NASDAQ:MARA). After reporting a meager $4.36 million in sales in 2020, Wall Street anticipates full-year sales will climb to $555 million by 2023. That's an increase of 12,629%.\nIf you're wondering how sales growth of this magnitude is possible for a company not involved in drug development, look no further than cryptocurrencies.\nMarathon Digital is a cryptocurrency mining company. It operates a farm of high-powered computing devices designed to solve complex mathematical equations that validate groups of transactions (known as a block) as valid on a digital currency's blockchain. For being the first to validate a block, Marathon is paid a block reward. This reward is typically a set amount of digital tokens from the digital currency being mined.\nIn Marathon's case, it's mining Bitcoin (CRYPTO:BTC), the largest cryptocurrency in the world by market cap. Being the first to mine a Bitcoin block results in the company being awarded 6.25 Bitcoin tokens, which were worth a cool $292,000, as of Aug. 30.\nThe reason Marathon's sales are skyrocketing so quickly is because it's in the midst of deploying one of the largest Bitcoin-mining operations in the United States. As of the beginning of August, approximately 30,100 miners were operating, with another 103,000 ordered and yet to be installed. By the end of the first quarter of 2022, Marathon should have north of 100,000 miners in operation, with all 133,120 up and running by July 2022.\nThough Marathon is the fastest-growing of these three hypergrowth stocks, it's also arguably the most dangerous investment of this trio. That's because it's entirely dependent on external factors, such as interest in, and the price of, Bitcoin -- and not innovation.\nWhat's more, the barrier to entry in the cryptocurrency mining space is virtually nonexistent. As time passes, it's going to be tougher for Marathon to successfully mine Bitcoin.\nAs the icing on the cake, Bitcoin's block rewards halve every four years. By 2024, only 3.125 Bitcoin tokens will be paid for validating a block. Essentially, Marathon is competing against a growing number of mining companies for a reward that's shrinking. It simply doesn't sound like an operating model with long-term staying power.","news_type":1},"isVote":1,"tweetType":1,"viewCount":123,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":812491358,"gmtCreate":1630599122674,"gmtModify":1631883610183,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>💪","listText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>💪","text":"$Alibaba(BABA)$💪","images":[{"img":"https://static.tigerbbs.com/e8c1109d86f6c89dde0e3f2939dfc1ac","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":1,"link":"https://laohu8.com/post/812491358","isVote":1,"tweetType":1,"viewCount":418,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":812347723,"gmtCreate":1630557193062,"gmtModify":1632472791006,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"👍👍","listText":"👍👍","text":"👍👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/812347723","repostId":"1121030066","repostType":4,"isVote":1,"tweetType":1,"viewCount":164,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":812344464,"gmtCreate":1630557086358,"gmtModify":1632472796910,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"keep going📈","listText":"keep going📈","text":"keep going📈","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/812344464","repostId":"1126364049","repostType":4,"isVote":1,"tweetType":1,"viewCount":151,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":812345335,"gmtCreate":1630556918727,"gmtModify":1631883826967,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"Good one","listText":"Good one","text":"Good one","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/812345335","repostId":"1105808841","repostType":4,"repost":{"id":"1105808841","kind":"news","pubTimestamp":1630547089,"share":"https://www.laohu8.com/m/news/1105808841?lang=&edition=full","pubTime":"2021-09-02 09:44","market":"hk","language":"en","title":"Hong Kong: Shares extend gains at open","url":"https://stock-news.laohu8.com/highlight/detail?id=1105808841","media":"AFP","summary":"[HONG KONG] Hong Kong stocks began with another advance on Thursday morning as investors bide their ","content":"<p>[HONG KONG] Hong Kong stocks began with another advance on Thursday morning as investors bide their time ahead of the release of key US jobs data at the end of the week.</p>\n<p>The Hang Seng Index rose 0.67 per cent or 175.23 points to 26,203.52.</p>\n<p>The Shanghai Composite dipped 0.20 per cent or 7.20 points to 3,559.90, while the Shenzhen Composite Index on China's second exchange fell 0.22 per cent or 5.32 points to 2,412.57.</p>","source":"lsy1605843958005","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong: Shares extend gains at open</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong: Shares extend gains at open\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-02 09:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.businesstimes.com.sg/stocks/hong-kong-shares-extend-gains-at-open-3><strong>AFP</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>[HONG KONG] Hong Kong stocks began with another advance on Thursday morning as investors bide their time ahead of the release of key US jobs data at the end of the week.\nThe Hang Seng Index rose 0.67 ...</p>\n\n<a href=\"https://www.businesstimes.com.sg/stocks/hong-kong-shares-extend-gains-at-open-3\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"HSI":"恒生指数"},"source_url":"https://www.businesstimes.com.sg/stocks/hong-kong-shares-extend-gains-at-open-3","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105808841","content_text":"[HONG KONG] Hong Kong stocks began with another advance on Thursday morning as investors bide their time ahead of the release of key US jobs data at the end of the week.\nThe Hang Seng Index rose 0.67 per cent or 175.23 points to 26,203.52.\nThe Shanghai Composite dipped 0.20 per cent or 7.20 points to 3,559.90, while the Shenzhen Composite Index on China's second exchange fell 0.22 per cent or 5.32 points to 2,412.57.","news_type":1},"isVote":1,"tweetType":1,"viewCount":58,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":816467328,"gmtCreate":1630514776964,"gmtModify":1632475021166,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"No idea&nbsp;","listText":"No idea&nbsp;","text":"No idea","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/816467328","repostId":"2164897643","repostType":4,"isVote":1,"tweetType":1,"viewCount":45,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":816465401,"gmtCreate":1630514617903,"gmtModify":1632475027101,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"Well, im newbie to us stocks😅","listText":"Well, im newbie to us stocks😅","text":"Well, im newbie to us stocks😅","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/816465401","repostId":"2164550813","repostType":4,"isVote":1,"tweetType":1,"viewCount":84,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":816635342,"gmtCreate":1630494582086,"gmtModify":1631884041956,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/G13.SI\">$GENTING SINGAPORE LIMITED(G13.SI)$</a>&nbsp;add on some units&nbsp;","listText":"<a href=\"https://laohu8.com/S/G13.SI\">$GENTING SINGAPORE LIMITED(G13.SI)$</a>&nbsp;add on some units&nbsp;","text":"$GENTING SINGAPORE LIMITED(G13.SI)$ add on some units","images":[{"img":"https://static.tigerbbs.com/9fe6678b5e4ece642003d70aab4f16ec","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/816635342","isVote":1,"tweetType":1,"viewCount":70,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":811849802,"gmtCreate":1630312489106,"gmtModify":1704958224997,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ME8U.SI\">$MAPLETREE INDUSTRIAL TRUST(ME8U.SI)$</a>💵💵","listText":"<a href=\"https://laohu8.com/S/ME8U.SI\">$MAPLETREE INDUSTRIAL TRUST(ME8U.SI)$</a>💵💵","text":"$MAPLETREE INDUSTRIAL TRUST(ME8U.SI)$💵💵","images":[{"img":"https://static.tigerbbs.com/476f8e5d98af48496099e1b473147679","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/811849802","isVote":1,"tweetType":1,"viewCount":56,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":811840800,"gmtCreate":1630312424800,"gmtModify":1704958223258,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BVA.SI\">$TOP GLOVE CORPORATION BHD(BVA.SI)$</a>&nbsp;please turn green soon...&nbsp;","listText":"<a href=\"https://laohu8.com/S/BVA.SI\">$TOP GLOVE CORPORATION BHD(BVA.SI)$</a>&nbsp;please turn green soon...&nbsp;","text":"$TOP GLOVE CORPORATION BHD(BVA.SI)$ please turn green soon...","images":[{"img":"https://static.tigerbbs.com/3c04aff57a9ab28e244905fdb0e2cdbc","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/811840800","isVote":1,"tweetType":1,"viewCount":86,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":819409852,"gmtCreate":1630081710576,"gmtModify":1704955767693,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"💪💪💪","listText":"💪💪💪","text":"💪💪💪","images":[{"img":"https://static.tigerbbs.com/5a7fe19ccee8cdb96b48cc9cb906b08f","width":"1080","height":"3192"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/819409852","isVote":1,"tweetType":1,"viewCount":133,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":812491358,"gmtCreate":1630599122674,"gmtModify":1631883610183,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>💪","listText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>💪","text":"$Alibaba(BABA)$💪","images":[{"img":"https://static.tigerbbs.com/e8c1109d86f6c89dde0e3f2939dfc1ac","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":1,"link":"https://laohu8.com/post/812491358","isVote":1,"tweetType":1,"viewCount":418,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":841987481,"gmtCreate":1635868657061,"gmtModify":1635868657061,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"What ww should buy right now?&nbsp;","listText":"What ww should buy right now?&nbsp;","text":"What ww should buy right now?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/841987481","repostId":"2180020937","repostType":4,"repost":{"id":"2180020937","kind":"news","pubTimestamp":1635846331,"share":"https://www.laohu8.com/m/news/2180020937?lang=&edition=full","pubTime":"2021-11-02 17:45","market":"us","language":"en","title":"Warren Buffett says this is the best type of business to own when inflation spikes — in other words, what you should buy right now","url":"https://stock-news.laohu8.com/highlight/detail?id=2180020937","media":"MoneyWise","summary":"Inflation is high. You might as well profit from it.High inflation rates in the country have become a serious concern on Wall Street.But fortunately for everyday investors, Berkshire Hathaway chief Warren Buffett has plenty of experience in navigating such an environment.Buffett managed a stock portfolio through periods of double-digit inflation rates in the 1970s and has plenty of advice on what to own when consumer prices spike.In a 1981 letter to Berkshire shareholders, Buffett highlighted tw","content":"<p>Inflation is high. You might as well profit from it.</p>\n<p><img src=\"https://static.tigerbbs.com/143c38befb27f09743294aafaffbe94a\" tg-width=\"1800\" tg-height=\"800\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>High inflation rates in the country have become a serious concern on Wall Street.</p>\n<p>But fortunately for everyday investors, Berkshire Hathaway chief Warren Buffett has plenty of experience in navigating such an environment.</p>\n<p>Buffett managed a stock portfolio through periods of double-digit inflation rates in the 1970s and has plenty of advice on what to own when consumer prices spike.</p>\n<p>In a 1981 letter to Berkshire shareholders, Buffett highlighted two characteristics that make a business well adapted to an inflationary environment: 1) an ability to increase prices easily, and 2) an ability to take on more business without having to spend too much in order to do it.</p>\n<p>In other words, aim to invest in asset-light businesses with pricing power.</p>\n<p>Let’s take a quick look at three companies that fit that description. One (or all) of them might be worth purchasing with your spare pennies.</p>\n<p><b>Nike (NKE)</b></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0a24fd7cb9b4e01313c7bb848af6da9d\" tg-width=\"1200\" tg-height=\"500\" width=\"100%\" height=\"auto\"><span>TY Lim/Shutterstock</span></p>\n<p>Nike is a global footwear powerhouse that commands high customer loyalty.</p>\n<p>Customers are willing to pay top dollar for signature gear associated with high-profile athletes like LeBron James and Michael Jordan.</p>\n<p>Despite inflationary pressures, Nike continues to expand gross margins and post solid returns on equity well above 30%.</p>\n<p>The company is also capturing the full price of its products in an increasingly digital, direct-to-consumer business model.</p>\n<p>Management believes digital sales could continue to grow from 20% of revenue currently to about 40% of the business by 2025. And price increases could kick in as early as next year.</p>\n<p>Amazingly, profit margins may keep expanding, even as operating costs rise with inflation.</p>\n<p>Nike shares are up about 19% so far in 2021.</p>\n<p><b>Apple (AAPL)</b></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b22460a66469a2da0380edd32d454c84\" tg-width=\"1200\" tg-height=\"500\" width=\"100%\" height=\"auto\"><span>Vytautas Kielaitis/Shutterstock</span></p>\n<p>Global demand for Apple’s premium-priced hardware is growing, as are adoption rates for its high-margin Apple services.</p>\n<p>Strong brand identity, user friendliness, and a wide range of fully integrated products are powerful attributes that aren’t going away any time soon.</p>\n<p>Customers just can’t afford to live outside the Apple ecosystem. That gives the tech giant more freedom to play with pricing as inflation spikes.</p>\n<p>The company’s latest M1 chips, which will gradually replace Intel’s CPUs in every single Mac, underscore its commitment to constant innovation.</p>\n<p>Apple’s ability to pass rising costs to a global consumer base without significant loss of sales volumes is undeniable.</p>\n<p>Warren Buffett has allowed Apple to grow to 40% of Berkshire Hathaway’s investments portfolio for good reason: The business just keeps growing profits through all economic cycles.</p>\n<p>Apple is up about 13% year to date and trades at nearly $150 per share. But if you’re on the fence about jumping in at the current level, some apps might give you a free share of Apple just for signing up.</p>\n<p><b>Levi Strauss &amp; Co. (LEVI)</b></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/71b31165e275a966ad050139a054c73a\" tg-width=\"1200\" tg-height=\"500\" width=\"100%\" height=\"auto\"><span>dean bertoncelj/Shutterstock</span></p>\n<p>A market leader in the denim business, Levi Strauss has been firing on all cylinders of late.</p>\n<p>Specifically, its well-known brand and a flexible business model have enabled management to grow the top line without sacrificing pricing power.</p>\n<p>In the most recent quarter, revenue increased 41% while adjusted gross margin improved 390 basis points to 57.5%.</p>\n<p>In fact, management proactively started adjusting its pricing for inflation back in 2020.</p>\n<p>The company also sources raw materials from 24 different countries. And that kind of supply chain diversification provides Levi Strauss with plenty of flexibility during times of crisis.</p>\n<p>Levi shares are up more than 30% in 2021.</p>\n<p><b>The ultimate 'forever asset'?</b></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d5d520eb27cdf18f25a787cd9145eb1b\" tg-width=\"1200\" tg-height=\"500\" width=\"100%\" height=\"auto\"><span>MNStudio/Shutterstock</span></p>\n<p>Warren Buffett once said that his favorite holding period is forever.</p>\n<p>But forever is a long time, and since companies rise and fall, growing your wealth by never selling a share may not be the best strategy.</p>\n<p>But there might be one inflation safe haven that's worth holding forever — U.S. farmland.</p>\n<p>No matter how high or fast consumer prices climb, people still need to eat. And it just so happens that Buffett’s good friend Bill Gates is America’s largest private owner of farmland.</p>\n<p>These days, new platforms allow you to invest in U.S. farmland by taking stake in a farm of your choice.</p>\n<p>You’ll earn cash income from the leasing fees and crop sales. And of course, you’ll benefit from any long-term appreciation on top of that.</p>\n<p><i>This article provides information only and should not be construed as advice. It is provided without warranty of any kind.</i></p>","source":"lsy1621813427262","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Warren Buffett says this is the best type of business to own when inflation spikes — in other words, what you should buy right now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWarren Buffett says this is the best type of business to own when inflation spikes — in other words, what you should buy right now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-02 17:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://moneywise.com/investing/stocks/warren-buffett-inflation-stocks><strong>MoneyWise</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Inflation is high. You might as well profit from it.\n\nHigh inflation rates in the country have become a serious concern on Wall Street.\nBut fortunately for everyday investors, Berkshire Hathaway chief...</p>\n\n<a href=\"https://moneywise.com/investing/stocks/warren-buffett-inflation-stocks\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BRK.B":"伯克希尔B","INTC":"英特尔","NKE":"耐克","AAPL":"苹果","BRK.A":"伯克希尔","LEVI":"李维斯"},"source_url":"https://moneywise.com/investing/stocks/warren-buffett-inflation-stocks","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2180020937","content_text":"Inflation is high. You might as well profit from it.\n\nHigh inflation rates in the country have become a serious concern on Wall Street.\nBut fortunately for everyday investors, Berkshire Hathaway chief Warren Buffett has plenty of experience in navigating such an environment.\nBuffett managed a stock portfolio through periods of double-digit inflation rates in the 1970s and has plenty of advice on what to own when consumer prices spike.\nIn a 1981 letter to Berkshire shareholders, Buffett highlighted two characteristics that make a business well adapted to an inflationary environment: 1) an ability to increase prices easily, and 2) an ability to take on more business without having to spend too much in order to do it.\nIn other words, aim to invest in asset-light businesses with pricing power.\nLet’s take a quick look at three companies that fit that description. One (or all) of them might be worth purchasing with your spare pennies.\nNike (NKE)\nTY Lim/Shutterstock\nNike is a global footwear powerhouse that commands high customer loyalty.\nCustomers are willing to pay top dollar for signature gear associated with high-profile athletes like LeBron James and Michael Jordan.\nDespite inflationary pressures, Nike continues to expand gross margins and post solid returns on equity well above 30%.\nThe company is also capturing the full price of its products in an increasingly digital, direct-to-consumer business model.\nManagement believes digital sales could continue to grow from 20% of revenue currently to about 40% of the business by 2025. And price increases could kick in as early as next year.\nAmazingly, profit margins may keep expanding, even as operating costs rise with inflation.\nNike shares are up about 19% so far in 2021.\nApple (AAPL)\nVytautas Kielaitis/Shutterstock\nGlobal demand for Apple’s premium-priced hardware is growing, as are adoption rates for its high-margin Apple services.\nStrong brand identity, user friendliness, and a wide range of fully integrated products are powerful attributes that aren’t going away any time soon.\nCustomers just can’t afford to live outside the Apple ecosystem. That gives the tech giant more freedom to play with pricing as inflation spikes.\nThe company’s latest M1 chips, which will gradually replace Intel’s CPUs in every single Mac, underscore its commitment to constant innovation.\nApple’s ability to pass rising costs to a global consumer base without significant loss of sales volumes is undeniable.\nWarren Buffett has allowed Apple to grow to 40% of Berkshire Hathaway’s investments portfolio for good reason: The business just keeps growing profits through all economic cycles.\nApple is up about 13% year to date and trades at nearly $150 per share. But if you’re on the fence about jumping in at the current level, some apps might give you a free share of Apple just for signing up.\nLevi Strauss & Co. (LEVI)\ndean bertoncelj/Shutterstock\nA market leader in the denim business, Levi Strauss has been firing on all cylinders of late.\nSpecifically, its well-known brand and a flexible business model have enabled management to grow the top line without sacrificing pricing power.\nIn the most recent quarter, revenue increased 41% while adjusted gross margin improved 390 basis points to 57.5%.\nIn fact, management proactively started adjusting its pricing for inflation back in 2020.\nThe company also sources raw materials from 24 different countries. And that kind of supply chain diversification provides Levi Strauss with plenty of flexibility during times of crisis.\nLevi shares are up more than 30% in 2021.\nThe ultimate 'forever asset'?\nMNStudio/Shutterstock\nWarren Buffett once said that his favorite holding period is forever.\nBut forever is a long time, and since companies rise and fall, growing your wealth by never selling a share may not be the best strategy.\nBut there might be one inflation safe haven that's worth holding forever — U.S. farmland.\nNo matter how high or fast consumer prices climb, people still need to eat. And it just so happens that Buffett’s good friend Bill Gates is America’s largest private owner of farmland.\nThese days, new platforms allow you to invest in U.S. farmland by taking stake in a farm of your choice.\nYou’ll earn cash income from the leasing fees and crop sales. And of course, you’ll benefit from any long-term appreciation on top of that.\nThis article provides information only and should not be construed as advice. It is provided without warranty of any kind.","news_type":1},"isVote":1,"tweetType":1,"viewCount":680,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":880828029,"gmtCreate":1631035271361,"gmtModify":1632904431077,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"Good question! What to buy now?&nbsp;","listText":"Good question! What to buy now?&nbsp;","text":"Good question! What to buy now?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/880828029","repostId":"1130130857","repostType":4,"repost":{"id":"1130130857","kind":"news","pubTimestamp":1631007146,"share":"https://www.laohu8.com/m/news/1130130857?lang=&edition=full","pubTime":"2021-09-07 17:32","market":"us","language":"en","title":"Strategists Say the Stock Market Could Struggle This Fall. What to Buy Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=1130130857","media":"Barron's","summary":"What a year this has been for the markets!Fueled by a torrent of monetary and fiscal stimulus, economic and earnings growth, and  a mostly receding pandemic, theS&P 500stock index has rallied 20%, notching seven straight months of gains and more than 50 highs along the way. And that’s on top of last year’s 68% rebound from the market’s March 2020 lows.Tailwinds remain in place, but headwinds now loom that could slow stocks’ advance. Stimulus spending has peaked, and economic and corporate-earnin","content":"<p>What a year this has been for the markets! Fueled by a torrent of monetary and fiscal stimulus, economic and earnings growth, and (until recently) a mostly receding pandemic, theS&amp;P 500stock index has rallied 20%, notching seven straight months of gains and more than 50 highs along the way. And that’s on top of last year’s 68% rebound from the market’s March 2020 lows.</p>\n<p>Tailwinds remain in place, but headwinds now loom that could slow stocks’ advance. Stimulus spending has peaked, and economic and corporate-earnings growth are likely to decelerate through the end of the year. What’s more, theFederal Reserve has all but promised to start tapering its bond buyingin coming months, and the Biden administration has proposed hiking corporate and personal tax rates. None of this is apt to sit well with holders of increasingly pricey shares.</p>\n<p>In other words,brace for a volatile fallin which conflicting forces buffet stocks, bonds, and investors. “The everything rally is behind us,” says Saira Malik, chief investment officer of global equities at Nuveen. “It’s not going to be a sharply rising economic tide that lifts all boats from here.”</p>\n<p>That’s the general consensus among the six market strategists and chief investment officers whom<i>Barron’s</i>recently consulted. All see the S&amp;P 500 ending the year near Thursday’s close of 4536. Their average target: 4585.</p>\n<p>Next year’s gains look muted, as well, relative to recent trends. The group expects the S&amp;P 500 to tack on another 6% in 2022, rising to about 4800.</p>\n<p><img src=\"https://static.tigerbbs.com/eb61c7b74b9b0f18a019afb4ac44ad59\" tg-width=\"300\" tg-height=\"645\" referrerpolicy=\"no-referrer\">With stocks trading for about 21 times the coming year’s expected earnings,bonds yielding little, and cash yielding less than nothing after accounting for inflation, investors face tough asset-allocation decisions. In place of the “everything rally,” which lifted fast-growing tech stocks, no-growth meme stocks, and the Dogecoins of the digital world, our market watchers recommend focusing on “quality” investments. In equities, that means shares of businesses with solid balance sheets, expanding profit margins, and ample and recurring free cash flow. Even if the averages do little in coming months, these stocks are likely to shine.</p>\n<p>The stock market’s massive rally in the past year was a gift of sorts from the Federal Reserve, which flooded the financial system with money to stave off theeconomic damage wrought by the Covid pandemic. Since March 2020, the U.S. central bank has been buying a combined $120 billion a month of U.S. Treasuries and mortgage-backed securities, while keeping its benchmark federal-funds rate target at 0% to 0.25%. These moves have depressed bond yields and pushed investors into riskier assets, including stocks.</p>\n<p>Fed Chairman Jerome <a href=\"https://laohu8.com/S/POWL\">Powell</a> has said that the central bank might begin to wind down, or taper, its emergency asset purchases sometime in the coming quarters, a move that could roil risk assets of all sorts. “For us, it’s very simple: Tapering is tightening,” says Mike Wilson, chief investment officer and chief U.S. equity strategist atMorgan Stanley.“It’s the first step away from maximum accommodation [by the Fed]. They’re being very calculated about it this time, but the bottom line is that it should have a negative effect on equity valuations.”</p>\n<p>The government’s stimulus spending, too, has peaked, the strategists note. Supplemental federal unemployment benefits of $300 a week expire as of Sept. 6. Although Congress seems likely to pass a bipartisan infrastructure bill this fall, the near-term economic impact will pale in comparison to the multiple rounds of stimulus introduced since March 2020.</p>\n<p><img src=\"https://static.tigerbbs.com/c2cb76c498c1c4c980139e3d0514c261\" tg-width=\"300\" tg-height=\"645\" referrerpolicy=\"no-referrer\">The bill includes about $550 billion in new spending—a fraction of the trillions authorized by previous laws—and it will be spread out over many years. The short-term boost that infrastructure stimulus will give to consumer spending, which accounts for almost 70% of U.S. growth domestic product, won’t come close to what the economy saw after millions of Americans received checks from the government this past year.</p>\n<p>A budget bill approved by Democrats only should follow the infrastructure bill, and include spending to support Medicare expansion, child-care funding, free community-college tuition, public housing, and climate-related measures, among other party priorities. Congress could vote to lift taxes on corporations and high-earning individuals to offset that spending—another near-term risk to the market.</p>\n<p><img src=\"https://static.tigerbbs.com/6693da658db16059fc99e08a7531675f\" tg-width=\"300\" tg-height=\"645\" referrerpolicy=\"no-referrer\">Other politically charged issues likewise could derail equities this fall. Congress needs to pass a debt-ceiling increase to fund the government, and a stop-gap spending bill later this month to avoid a <a href=\"https://laohu8.com/S/WASH\">Washington</a> shutdown in October.</p>\n<p>For now, our market experts are relatively sanguine about the economic impact of the Delta variant of Covid-19. As long as vaccines remain effective in minimizing severe infections that lead to hospitalizations and deaths, the negative effects of the current Covid wave will be limited largely to the travel industry and movie theaters, they say. Wall Street’s base case for the market doesn’t include a renewed wave of lockdowns that would undermine economic growth.</p>\n<p>Inflation has been a hot topic at the Fed and among investors, partly because it has been running so hot of late. The U.S. consumer price index rose at an annualized 5.4% in both June and July—a spike the Fed calls transitory, although others aren’t so sure. The strategists are taking Powell’s side of the argument; they expect inflation to fall significantly next year. Their forecasts fall between 2.5% and 3.5%, which they consider manageable for consumers and companies, and an acceptable side effect of rapid economic growth. An inflation rate above 2.5%, however, combined with Fed tapering, would mean that now ultralow bond yields should rise.</p>\n<p>“We think inflation will continue to run hotter than it has since the financial crisis, but it’s hard for us to see inflation much over 2.5% once many of the reopening-related pressures start to dissipate,” says Michael Fredericks, head of income investing for theBlackRockMulti-Asset Strategies Group. “So bond yields do need to move up, but that will happen gradually.”</p>\n<p>The strategists see the yield on the 10-year U.S. Treasury note climbing to around 1.65% by year end. That’s about 35 basis points—or hundredths of a percentage point—above current levels, but below the 1.75% that the yield reached at its March 2021 highs. By next year, the 10-year Treasury could yield 2%, the group says. Those aren’t big moves in absolute terms, but they’re meaningful for&nbsp;the bond market—and could be even more so for stocks.</p>\n<p>Rising yields tend to weigh on stock valuations for two reasons. Higher-yielding bonds offer competition to stocks, and companies’ future earnings are worthless in the present when discounting them at a higher rate. Still, a 10-year yield around 2% won’t be enough to knock stock valuations down to pre-Covid levels. Even if yields climb, market strategists see the price/earnings multiple of the S&amp;P 500 holding well above its 30-year average of 16 times forward earnings. The index’s forward P/E topped 23 last fall.</p>\n<p><img src=\"https://static.tigerbbs.com/e08d24cb421d7cc13debd76a9c6fea01\" tg-width=\"660\" tg-height=\"434\" referrerpolicy=\"no-referrer\"></p>\n<p>As long as 10-year Treasury yields stay in the 2% range, the S&amp;P 500 should be able to command a forward P/E in the high teens, strategists say. A return to the 16-times long-term average isn’t in the cards until there is more pressure from much higher yields—or something else that causes stocks to fall.</p>\n<p>If yields surge past 2% or 2.25%, investors could start to question equity valuations more seriously, says&nbsp;<a href=\"https://laohu8.com/S/STT\">State</a> Street’schief portfolio strategist, Gaurav Mallik: “We haven’t seen [the 10-year yield] above 2% for some time now, so that’s an important sentiment level for investors.”</p>\n<p><img src=\"https://static.tigerbbs.com/93ff6490069ab5dc1b4057f1ff7966f3\" tg-width=\"664\" tg-height=\"441\" referrerpolicy=\"no-referrer\"></p>\n<p>Wilson is more concerned, noting that the stock market’s valuation risk is asymmetric: “It’s very unlikely that multiples are going to go up, and there’s a good chance that they go down more than 10% given the deceleration in growth and where we are in the cycle,” he says</p>\n<p>If 16 to 23 times forward earnings is the range, he adds, “you’re already at the very high end of that. There’s more potential risk than reward.”</p>\n<p>Some P/E-multiple compression is baked into all six strategists’ forecasts, heaping greater importance on the path of profit growth. On average, the strategists expect S&amp;P 500 earnings to jump 46% this year, to about $204, after last year’s earnings depression. That could be followed by a more normalized gain of 9% in 2022, to about $222.50.</p>\n<p>A potential headwind would be a higher federal corporate-tax rate in 2022. The details of Democrats’ spending and taxation plans will be worked out in the coming weeks, and investors can expect to hear a lot more about potential tax increases. Several strategists see a 25% federal rate on corporate profits as a likely compromise figure, above the 21% in place since 2018, but below the 28% sought by the Biden administration.</p>\n<p>An increase of that magnitude would shave about 5% off S&amp;P 500 earnings next year. The index could drop by a similar amount as the passage of the Democrats’ reconciliation bill nears this fall, but the impact should be limited to that initial correction. As with the tax cuts in December 2017, the change should be a <a href=\"https://laohu8.com/S/AONE.U\">one</a>-time event for the market, some strategists predict.</p>\n<p>These concerns aside, investors shouldn’t miss the bigger picture: The U.S. economy is in good shape and growing robustly. The strategists expect gross domestic product to rise 6.3% this year and about 4% in 2022. “The cyclical uplift and above-trend growth will continue at least through 2022, and we want to be biased toward assets that have that exposure,” says Mallik.</p>\n<blockquote>\n “We’re going to have a hot economy this year and next. When GDP growth is above average, value beats growth and cyclicals beat defensives.”— Lori Calvasina, RBC Capital Markets\n</blockquote>\n<p>The State Street strategist recommends overweighting materials, financials, and technology in investment portfolios. That approach includes both economically sensitive companies, such as banks and miners, and steady growers in the tech sector.</p>\n<p>RBC Capital Markets’ head of U.S. equity strategy, Lori Calvasina, likewise takes a barbell approach, with both cyclical and growth exposure. Her preferred sectors are energy, financials, and technology.</p>\n<p>“Valuations are still a lot more attractive in financials and energy than growth [sectors such as technology or consumer discretionary,]” Calvasina says. “The catalyst in the near term is getting out of the current Covid wave... We’re going to have a hot economy this year and next, and traditionally when GDP growth is above average, value beats growth and cyclicals beat defensives.”</p>\n<p>But the focus on quality will be pivotal, especially moving into the second half of 2022. That’s when the Fed is likely to hike interest rates for the first time in this cycle. By 2023, the economy could return to pre-Covid growth on the order of 2%.</p>\n<p>“The historical playbook is that coming out of a recession, you tend to see low-quality outperformance that lasts about a year, then leadership flips back to high quality,” Calvasina says. “But that transition from low quality back to high quality tends to be very bumpy.”</p>\n<p><b>A Shopping List for Fall</b></p>\n<p>Most strategists favor a combination of economically sensitive stocks and steady growers, including tech shares. Financials should do well, particularly if bond yields rise.</p>\n<p><img src=\"https://static.tigerbbs.com/a54c4bd114c1a5f7f700d1fc14d30d8e\" tg-width=\"970\" tg-height=\"230\" referrerpolicy=\"no-referrer\"></p>\n<p>Although stocks with quality attributes have outperformed the market this summer, according to a <a href=\"https://laohu8.com/S/BLK\">BlackRock</a> analysis, the quality factor has lagged since positive vaccine news was first reported last November.</p>\n<p>“We’re moving into a mid-cycle environment, when underlying economic growth remains strong but momentum begins to decelerate,” BlackRock’s Fredericks says. “Our research shows that quality stocks perform particularly well in such a period.”</p>\n<p>He recommends overweighting profitable technology companies; financials, including banks, and consumer staples and industrials with those quality characteristics.</p>\n<p>For <a href=\"https://laohu8.com/S/WFC\">Wells Fargo</a>’s head of equity strategy, Christopher Harvey, a mix of post-pandemic beneficiaries and defensive exposure is the way to go. He constructed a basket of stocks with lower-than-average volatility—which should outperform during periods of market uncertainty or stress this fall—and high “Covid beta,” or sensitivity to good or bad news about the pandemic. One requirement; The stocks had to be rated the equivalent of Buy by Wells Fargo’s equity analysts.</p>\n<p>“There’s near-term economic uncertainty, interest-rate uncertainty, and Covid risk, and generally we’re in a seasonally weaker part of the year around September,” says Harvey. “If we can balance low vol and high Covid beta, we can mitigate a lot of the upcoming uncertainty and volatility around timing of several of those catalysts. Longer-term, though, we still want to have that [reopening exposure.]”</p>\n<p>Harvey’s list of low-volatility stocks with high Covid beta includesApple(AAPL),<a href=\"https://laohu8.com/S/BAC\">Bank of America</a>(BAC),<a href=\"https://laohu8.com/S/NTRSP\">Northern</a> Trust(NTRS),Lowe’s(LOW),<a href=\"https://laohu8.com/S/IQV\">IQVIA</a> Holdings(IQV), andMasco(MAS).</p>\n<p>Overall, banks are the most frequently recommended group for the months ahead. TheInvesco KBW Bankexchange-traded fund (KBWB) provides broad exposure to the sector in the U.S.</p>\n<p>“We like the valuations [and] credit quality; they are now allowed to buy back shares and increase dividends, and there’s higher Covid beta,” says Harvey.</p>\n<p>Cheaper valuations mean less potential downside in a market correction. And, contrary to much of the rest of the stock market, higher interest rates would be a tailwind for the banks, which could then charge more for loans.</p>\n<p><a href=\"https://laohu8.com/S/HCSG\">Healthcare</a> stocks also have some fans. “<a href=\"https://laohu8.com/S/HR\">Healthcare</a> has both defensive and growth attributes to it,” Wilson says. “You’re paying a lot less per unit of growth in healthcare today than you are in other sectors. So we think it provides good balance in this market when we’re worried about valuation.” Health insurerHumana(HUM) makes Wilson’s “Fresh Money Buy List” of stocks Buy-rated by <a href=\"https://laohu8.com/S/MS\">Morgan Stanley</a> analysts and fitting his macro views.</p>\n<p>Nuveen’s Malik is also looking toward health care for relatively underpriced growth exposure, namely in the pharmaceuticals and biotechnology groups. She points toSeagen(SGEN), which is focused on oncology drugs and could be an attractive acquisition target for a pharma giant.</p>\n<p>Malik also likesAbbVie(ABBV) which trades at an undemanding eight times forward earnings and sports a 4.7% dividend yield. The coming expiration of patents on its blockbuster anti-inflammatory drug Humira has kept some investors away, but Malik is confident that management can limit the damage and sees promising drugs in development at the $200 billion company.</p>\n<p>Both stocks have had a tough time in recent days. Seagen fell more than 8% last week, to around $152, on news that its co-founder and CEO sold a large number of shares recently. AndAbbVietanked 7% Wednesday, to $112.27, after the Food and Drug Administration required new warning labels for JAK inhibitors, a type of anti-rheumatoid drug that includes one of <a href=\"https://laohu8.com/S/ABBV\">AbbVie</a>’s most promising post-Humira products.</p>\n<p><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>(PFE),<a href=\"https://laohu8.com/S/AXP\">American Express</a>(AXP),Johnson &amp; Johnson(JNJ), andCisco Systems(CSCO) are other S&amp;P 500 members that pass a<i>Barron’s</i>screen for quality attributes.</p>\n<p>After a year of steady gains, investors might be reminded this fall that stocks can also decline, as growth momentum and policy support begin to fade. But underlying economic strength supports buying the dip, should the market drop from its highs. <a href=\"https://laohu8.com/S/JE\">Just</a> be more selective. And go with quality.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Strategists Say the Stock Market Could Struggle This Fall. What to Buy Now?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStrategists Say the Stock Market Could Struggle This Fall. What to Buy Now?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-07 17:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/stocks-could-struggle-this-fall-market-strategists-say-stick-with-quality-companies-51630699840?siteid=yhoof2><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What a year this has been for the markets! Fueled by a torrent of monetary and fiscal stimulus, economic and earnings growth, and (until recently) a mostly receding pandemic, theS&P 500stock index has...</p>\n\n<a href=\"https://www.barrons.com/articles/stocks-could-struggle-this-fall-market-strategists-say-stick-with-quality-companies-51630699840?siteid=yhoof2\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite","SPY":"标普500ETF",".SPX":"S&P 500 Index"},"source_url":"https://www.barrons.com/articles/stocks-could-struggle-this-fall-market-strategists-say-stick-with-quality-companies-51630699840?siteid=yhoof2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130130857","content_text":"What a year this has been for the markets! Fueled by a torrent of monetary and fiscal stimulus, economic and earnings growth, and (until recently) a mostly receding pandemic, theS&P 500stock index has rallied 20%, notching seven straight months of gains and more than 50 highs along the way. And that’s on top of last year’s 68% rebound from the market’s March 2020 lows.\nTailwinds remain in place, but headwinds now loom that could slow stocks’ advance. Stimulus spending has peaked, and economic and corporate-earnings growth are likely to decelerate through the end of the year. What’s more, theFederal Reserve has all but promised to start tapering its bond buyingin coming months, and the Biden administration has proposed hiking corporate and personal tax rates. None of this is apt to sit well with holders of increasingly pricey shares.\nIn other words,brace for a volatile fallin which conflicting forces buffet stocks, bonds, and investors. “The everything rally is behind us,” says Saira Malik, chief investment officer of global equities at Nuveen. “It’s not going to be a sharply rising economic tide that lifts all boats from here.”\nThat’s the general consensus among the six market strategists and chief investment officers whomBarron’srecently consulted. All see the S&P 500 ending the year near Thursday’s close of 4536. Their average target: 4585.\nNext year’s gains look muted, as well, relative to recent trends. The group expects the S&P 500 to tack on another 6% in 2022, rising to about 4800.\nWith stocks trading for about 21 times the coming year’s expected earnings,bonds yielding little, and cash yielding less than nothing after accounting for inflation, investors face tough asset-allocation decisions. In place of the “everything rally,” which lifted fast-growing tech stocks, no-growth meme stocks, and the Dogecoins of the digital world, our market watchers recommend focusing on “quality” investments. In equities, that means shares of businesses with solid balance sheets, expanding profit margins, and ample and recurring free cash flow. Even if the averages do little in coming months, these stocks are likely to shine.\nThe stock market’s massive rally in the past year was a gift of sorts from the Federal Reserve, which flooded the financial system with money to stave off theeconomic damage wrought by the Covid pandemic. Since March 2020, the U.S. central bank has been buying a combined $120 billion a month of U.S. Treasuries and mortgage-backed securities, while keeping its benchmark federal-funds rate target at 0% to 0.25%. These moves have depressed bond yields and pushed investors into riskier assets, including stocks.\nFed Chairman Jerome Powell has said that the central bank might begin to wind down, or taper, its emergency asset purchases sometime in the coming quarters, a move that could roil risk assets of all sorts. “For us, it’s very simple: Tapering is tightening,” says Mike Wilson, chief investment officer and chief U.S. equity strategist atMorgan Stanley.“It’s the first step away from maximum accommodation [by the Fed]. They’re being very calculated about it this time, but the bottom line is that it should have a negative effect on equity valuations.”\nThe government’s stimulus spending, too, has peaked, the strategists note. Supplemental federal unemployment benefits of $300 a week expire as of Sept. 6. Although Congress seems likely to pass a bipartisan infrastructure bill this fall, the near-term economic impact will pale in comparison to the multiple rounds of stimulus introduced since March 2020.\nThe bill includes about $550 billion in new spending—a fraction of the trillions authorized by previous laws—and it will be spread out over many years. The short-term boost that infrastructure stimulus will give to consumer spending, which accounts for almost 70% of U.S. growth domestic product, won’t come close to what the economy saw after millions of Americans received checks from the government this past year.\nA budget bill approved by Democrats only should follow the infrastructure bill, and include spending to support Medicare expansion, child-care funding, free community-college tuition, public housing, and climate-related measures, among other party priorities. Congress could vote to lift taxes on corporations and high-earning individuals to offset that spending—another near-term risk to the market.\nOther politically charged issues likewise could derail equities this fall. Congress needs to pass a debt-ceiling increase to fund the government, and a stop-gap spending bill later this month to avoid a Washington shutdown in October.\nFor now, our market experts are relatively sanguine about the economic impact of the Delta variant of Covid-19. As long as vaccines remain effective in minimizing severe infections that lead to hospitalizations and deaths, the negative effects of the current Covid wave will be limited largely to the travel industry and movie theaters, they say. Wall Street’s base case for the market doesn’t include a renewed wave of lockdowns that would undermine economic growth.\nInflation has been a hot topic at the Fed and among investors, partly because it has been running so hot of late. The U.S. consumer price index rose at an annualized 5.4% in both June and July—a spike the Fed calls transitory, although others aren’t so sure. The strategists are taking Powell’s side of the argument; they expect inflation to fall significantly next year. Their forecasts fall between 2.5% and 3.5%, which they consider manageable for consumers and companies, and an acceptable side effect of rapid economic growth. An inflation rate above 2.5%, however, combined with Fed tapering, would mean that now ultralow bond yields should rise.\n“We think inflation will continue to run hotter than it has since the financial crisis, but it’s hard for us to see inflation much over 2.5% once many of the reopening-related pressures start to dissipate,” says Michael Fredericks, head of income investing for theBlackRockMulti-Asset Strategies Group. “So bond yields do need to move up, but that will happen gradually.”\nThe strategists see the yield on the 10-year U.S. Treasury note climbing to around 1.65% by year end. That’s about 35 basis points—or hundredths of a percentage point—above current levels, but below the 1.75% that the yield reached at its March 2021 highs. By next year, the 10-year Treasury could yield 2%, the group says. Those aren’t big moves in absolute terms, but they’re meaningful for the bond market—and could be even more so for stocks.\nRising yields tend to weigh on stock valuations for two reasons. Higher-yielding bonds offer competition to stocks, and companies’ future earnings are worthless in the present when discounting them at a higher rate. Still, a 10-year yield around 2% won’t be enough to knock stock valuations down to pre-Covid levels. Even if yields climb, market strategists see the price/earnings multiple of the S&P 500 holding well above its 30-year average of 16 times forward earnings. The index’s forward P/E topped 23 last fall.\n\nAs long as 10-year Treasury yields stay in the 2% range, the S&P 500 should be able to command a forward P/E in the high teens, strategists say. A return to the 16-times long-term average isn’t in the cards until there is more pressure from much higher yields—or something else that causes stocks to fall.\nIf yields surge past 2% or 2.25%, investors could start to question equity valuations more seriously, says State Street’schief portfolio strategist, Gaurav Mallik: “We haven’t seen [the 10-year yield] above 2% for some time now, so that’s an important sentiment level for investors.”\n\nWilson is more concerned, noting that the stock market’s valuation risk is asymmetric: “It’s very unlikely that multiples are going to go up, and there’s a good chance that they go down more than 10% given the deceleration in growth and where we are in the cycle,” he says\nIf 16 to 23 times forward earnings is the range, he adds, “you’re already at the very high end of that. There’s more potential risk than reward.”\nSome P/E-multiple compression is baked into all six strategists’ forecasts, heaping greater importance on the path of profit growth. On average, the strategists expect S&P 500 earnings to jump 46% this year, to about $204, after last year’s earnings depression. That could be followed by a more normalized gain of 9% in 2022, to about $222.50.\nA potential headwind would be a higher federal corporate-tax rate in 2022. The details of Democrats’ spending and taxation plans will be worked out in the coming weeks, and investors can expect to hear a lot more about potential tax increases. Several strategists see a 25% federal rate on corporate profits as a likely compromise figure, above the 21% in place since 2018, but below the 28% sought by the Biden administration.\nAn increase of that magnitude would shave about 5% off S&P 500 earnings next year. The index could drop by a similar amount as the passage of the Democrats’ reconciliation bill nears this fall, but the impact should be limited to that initial correction. As with the tax cuts in December 2017, the change should be a one-time event for the market, some strategists predict.\nThese concerns aside, investors shouldn’t miss the bigger picture: The U.S. economy is in good shape and growing robustly. The strategists expect gross domestic product to rise 6.3% this year and about 4% in 2022. “The cyclical uplift and above-trend growth will continue at least through 2022, and we want to be biased toward assets that have that exposure,” says Mallik.\n\n “We’re going to have a hot economy this year and next. When GDP growth is above average, value beats growth and cyclicals beat defensives.”— Lori Calvasina, RBC Capital Markets\n\nThe State Street strategist recommends overweighting materials, financials, and technology in investment portfolios. That approach includes both economically sensitive companies, such as banks and miners, and steady growers in the tech sector.\nRBC Capital Markets’ head of U.S. equity strategy, Lori Calvasina, likewise takes a barbell approach, with both cyclical and growth exposure. Her preferred sectors are energy, financials, and technology.\n“Valuations are still a lot more attractive in financials and energy than growth [sectors such as technology or consumer discretionary,]” Calvasina says. “The catalyst in the near term is getting out of the current Covid wave... We’re going to have a hot economy this year and next, and traditionally when GDP growth is above average, value beats growth and cyclicals beat defensives.”\nBut the focus on quality will be pivotal, especially moving into the second half of 2022. That’s when the Fed is likely to hike interest rates for the first time in this cycle. By 2023, the economy could return to pre-Covid growth on the order of 2%.\n“The historical playbook is that coming out of a recession, you tend to see low-quality outperformance that lasts about a year, then leadership flips back to high quality,” Calvasina says. “But that transition from low quality back to high quality tends to be very bumpy.”\nA Shopping List for Fall\nMost strategists favor a combination of economically sensitive stocks and steady growers, including tech shares. Financials should do well, particularly if bond yields rise.\n\nAlthough stocks with quality attributes have outperformed the market this summer, according to a BlackRock analysis, the quality factor has lagged since positive vaccine news was first reported last November.\n“We’re moving into a mid-cycle environment, when underlying economic growth remains strong but momentum begins to decelerate,” BlackRock’s Fredericks says. “Our research shows that quality stocks perform particularly well in such a period.”\nHe recommends overweighting profitable technology companies; financials, including banks, and consumer staples and industrials with those quality characteristics.\nFor Wells Fargo’s head of equity strategy, Christopher Harvey, a mix of post-pandemic beneficiaries and defensive exposure is the way to go. He constructed a basket of stocks with lower-than-average volatility—which should outperform during periods of market uncertainty or stress this fall—and high “Covid beta,” or sensitivity to good or bad news about the pandemic. One requirement; The stocks had to be rated the equivalent of Buy by Wells Fargo’s equity analysts.\n“There’s near-term economic uncertainty, interest-rate uncertainty, and Covid risk, and generally we’re in a seasonally weaker part of the year around September,” says Harvey. “If we can balance low vol and high Covid beta, we can mitigate a lot of the upcoming uncertainty and volatility around timing of several of those catalysts. Longer-term, though, we still want to have that [reopening exposure.]”\nHarvey’s list of low-volatility stocks with high Covid beta includesApple(AAPL),Bank of America(BAC),Northern Trust(NTRS),Lowe’s(LOW),IQVIA Holdings(IQV), andMasco(MAS).\nOverall, banks are the most frequently recommended group for the months ahead. TheInvesco KBW Bankexchange-traded fund (KBWB) provides broad exposure to the sector in the U.S.\n“We like the valuations [and] credit quality; they are now allowed to buy back shares and increase dividends, and there’s higher Covid beta,” says Harvey.\nCheaper valuations mean less potential downside in a market correction. And, contrary to much of the rest of the stock market, higher interest rates would be a tailwind for the banks, which could then charge more for loans.\nHealthcare stocks also have some fans. “Healthcare has both defensive and growth attributes to it,” Wilson says. “You’re paying a lot less per unit of growth in healthcare today than you are in other sectors. So we think it provides good balance in this market when we’re worried about valuation.” Health insurerHumana(HUM) makes Wilson’s “Fresh Money Buy List” of stocks Buy-rated by Morgan Stanley analysts and fitting his macro views.\nNuveen’s Malik is also looking toward health care for relatively underpriced growth exposure, namely in the pharmaceuticals and biotechnology groups. She points toSeagen(SGEN), which is focused on oncology drugs and could be an attractive acquisition target for a pharma giant.\nMalik also likesAbbVie(ABBV) which trades at an undemanding eight times forward earnings and sports a 4.7% dividend yield. The coming expiration of patents on its blockbuster anti-inflammatory drug Humira has kept some investors away, but Malik is confident that management can limit the damage and sees promising drugs in development at the $200 billion company.\nBoth stocks have had a tough time in recent days. Seagen fell more than 8% last week, to around $152, on news that its co-founder and CEO sold a large number of shares recently. AndAbbVietanked 7% Wednesday, to $112.27, after the Food and Drug Administration required new warning labels for JAK inhibitors, a type of anti-rheumatoid drug that includes one of AbbVie’s most promising post-Humira products.\nPfizer(PFE),American Express(AXP),Johnson & Johnson(JNJ), andCisco Systems(CSCO) are other S&P 500 members that pass aBarron’sscreen for quality attributes.\nAfter a year of steady gains, investors might be reminded this fall that stocks can also decline, as growth momentum and policy support begin to fade. But underlying economic strength supports buying the dip, should the market drop from its highs. Just be more selective. And go with quality.","news_type":1},"isVote":1,"tweetType":1,"viewCount":175,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":817166739,"gmtCreate":1630920332921,"gmtModify":1631887920368,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ME8U.SI\">$MAPLETREE INDUSTRIAL TRUST(ME8U.SI)$</a>🤑","listText":"<a href=\"https://laohu8.com/S/ME8U.SI\">$MAPLETREE INDUSTRIAL TRUST(ME8U.SI)$</a>🤑","text":"$MAPLETREE INDUSTRIAL TRUST(ME8U.SI)$🤑","images":[{"img":"https://static.tigerbbs.com/c4d3fadb9d9dc8ae8804d10ac4f6904e","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/817166739","isVote":1,"tweetType":1,"viewCount":363,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":819888278,"gmtCreate":1630054512994,"gmtModify":1704955249104,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ME8U.SI\">$MAPLETREE INDUSTRIAL TRUST(ME8U.SI)$</a>💪","listText":"<a href=\"https://laohu8.com/S/ME8U.SI\">$MAPLETREE INDUSTRIAL TRUST(ME8U.SI)$</a>💪","text":"$MAPLETREE INDUSTRIAL TRUST(ME8U.SI)$💪","images":[{"img":"https://static.tigerbbs.com/7aa506f56265080f7406a2cc1fb383a1","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/819888278","isVote":1,"tweetType":1,"viewCount":41,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":817165360,"gmtCreate":1630920535050,"gmtModify":1631885788150,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AP4.SI\">$RIVERSTONE HOLDINGS LIMITED(AP4.SI)$</a>&nbsp;hmmm.... If 👇&nbsp;again i ll average 👇&nbsp;","listText":"<a href=\"https://laohu8.com/S/AP4.SI\">$RIVERSTONE HOLDINGS LIMITED(AP4.SI)$</a>&nbsp;hmmm.... If 👇&nbsp;again i ll average 👇&nbsp;","text":"$RIVERSTONE HOLDINGS LIMITED(AP4.SI)$ hmmm.... If 👇 again i ll average 👇","images":[{"img":"https://static.tigerbbs.com/b7ce034ea1f1dd6a03ce00365ca929b1","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/817165360","isVote":1,"tweetType":1,"viewCount":485,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":816465401,"gmtCreate":1630514617903,"gmtModify":1632475027101,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"Well, im newbie to us stocks😅","listText":"Well, im newbie to us stocks😅","text":"Well, im newbie to us stocks😅","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/816465401","repostId":"2164550813","repostType":4,"isVote":1,"tweetType":1,"viewCount":84,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":819409852,"gmtCreate":1630081710576,"gmtModify":1704955767693,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"💪💪💪","listText":"💪💪💪","text":"💪💪💪","images":[{"img":"https://static.tigerbbs.com/5a7fe19ccee8cdb96b48cc9cb906b08f","width":"1080","height":"3192"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/819409852","isVote":1,"tweetType":1,"viewCount":133,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":812344464,"gmtCreate":1630557086358,"gmtModify":1632472796910,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"keep going📈","listText":"keep going📈","text":"keep going📈","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/812344464","repostId":"1126364049","repostType":4,"isVote":1,"tweetType":1,"viewCount":151,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":811840800,"gmtCreate":1630312424800,"gmtModify":1704958223258,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BVA.SI\">$TOP GLOVE CORPORATION BHD(BVA.SI)$</a>&nbsp;please turn green soon...&nbsp;","listText":"<a href=\"https://laohu8.com/S/BVA.SI\">$TOP GLOVE CORPORATION BHD(BVA.SI)$</a>&nbsp;please turn green soon...&nbsp;","text":"$TOP GLOVE CORPORATION BHD(BVA.SI)$ please turn green soon...","images":[{"img":"https://static.tigerbbs.com/3c04aff57a9ab28e244905fdb0e2cdbc","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/811840800","isVote":1,"tweetType":1,"viewCount":86,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":843734429,"gmtCreate":1635858032191,"gmtModify":1635858032191,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"booster","listText":"booster","text":"booster","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/843734429","repostId":"1193558756","repostType":4,"repost":{"id":"1193558756","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635850584,"share":"https://www.laohu8.com/m/news/1193558756?lang=&edition=full","pubTime":"2021-11-02 18:56","market":"us","language":"en","title":"Pfizer rose over 2% in premarket trading as it raised COVID-19 vaccine sales forecast to $36 bln for 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=1193558756","media":"Tiger Newspress","summary":"Pfizer Inc on Tuesday raised the full-year sales forecast for its COVID-19 vaccine by 7.5% to $36 bi","content":"<p>Pfizer Inc&nbsp;on Tuesday raised the full-year sales forecast for its COVID-19 vaccine by 7.5% to $36 billion, as it signs deals with countries for booster doses and receives clearances for using its shots in children.</p>\n<p>The company had in July forecast sales of $33.5 billion from the vaccine it sells with BioNTech .</p>\n<p>Driven by an unprecedented vaccination drive against the COVID-19 pandemic globally, Pfizer's shot has quickly become one of the best-selling products in the company's roughly 172-year history.</p>\n<p>The company, which was well known for drugs such as Xanax and Viagra, equally splits expenses and profit with its German partner.</p>\n<p>Pfizer expects to deliver 2.3 billion doses of the vaccine, out of the roughly 3 billion it expects to make this year.</p>\n<p>Its&nbsp;shares&nbsp;rose&nbsp;over 2% in premarket trading.<img src=\"https://static.tigerbbs.com/df663bc64292fce6036a0c102eb67471\" tg-width=\"770\" tg-height=\"566\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer rose over 2% in premarket trading as it raised COVID-19 vaccine sales forecast to $36 bln for 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer rose over 2% in premarket trading as it raised COVID-19 vaccine sales forecast to $36 bln for 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-02 18:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pfizer Inc&nbsp;on Tuesday raised the full-year sales forecast for its COVID-19 vaccine by 7.5% to $36 billion, as it signs deals with countries for booster doses and receives clearances for using its shots in children.</p>\n<p>The company had in July forecast sales of $33.5 billion from the vaccine it sells with BioNTech .</p>\n<p>Driven by an unprecedented vaccination drive against the COVID-19 pandemic globally, Pfizer's shot has quickly become one of the best-selling products in the company's roughly 172-year history.</p>\n<p>The company, which was well known for drugs such as Xanax and Viagra, equally splits expenses and profit with its German partner.</p>\n<p>Pfizer expects to deliver 2.3 billion doses of the vaccine, out of the roughly 3 billion it expects to make this year.</p>\n<p>Its&nbsp;shares&nbsp;rose&nbsp;over 2% in premarket trading.<img src=\"https://static.tigerbbs.com/df663bc64292fce6036a0c102eb67471\" tg-width=\"770\" tg-height=\"566\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1193558756","content_text":"Pfizer Inc on Tuesday raised the full-year sales forecast for its COVID-19 vaccine by 7.5% to $36 billion, as it signs deals with countries for booster doses and receives clearances for using its shots in children.\nThe company had in July forecast sales of $33.5 billion from the vaccine it sells with BioNTech .\nDriven by an unprecedented vaccination drive against the COVID-19 pandemic globally, Pfizer's shot has quickly become one of the best-selling products in the company's roughly 172-year history.\nThe company, which was well known for drugs such as Xanax and Viagra, equally splits expenses and profit with its German partner.\nPfizer expects to deliver 2.3 billion doses of the vaccine, out of the roughly 3 billion it expects to make this year.\nIts shares rose over 2% in premarket trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":533,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":812347723,"gmtCreate":1630557193062,"gmtModify":1632472791006,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"👍👍","listText":"👍👍","text":"👍👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/812347723","repostId":"1121030066","repostType":4,"isVote":1,"tweetType":1,"viewCount":164,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":816467328,"gmtCreate":1630514776964,"gmtModify":1632475021166,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"No idea&nbsp;","listText":"No idea&nbsp;","text":"No idea","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/816467328","repostId":"2164897643","repostType":4,"isVote":1,"tweetType":1,"viewCount":45,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":815268068,"gmtCreate":1630681235854,"gmtModify":1632467193337,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"Not sure is it&nbsp;good price to enter, but just do it💪💪","listText":"Not sure is it&nbsp;good price to enter, but just do it💪💪","text":"Not sure is it good price to enter, but just do it💪💪","images":[{"img":"https://static.tigerbbs.com/c36c1c4fa06c4203edd1ee21ea207bc7","width":"1080","height":"3192"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/815268068","isVote":1,"tweetType":1,"viewCount":276,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":815260728,"gmtCreate":1630681069064,"gmtModify":1632467220336,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"Tgif","listText":"Tgif","text":"Tgif","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/815260728","repostId":"2164879370","repostType":4,"repost":{"id":"2164879370","kind":"highlight","pubTimestamp":1630678680,"share":"https://www.laohu8.com/m/news/2164879370?lang=&edition=full","pubTime":"2021-09-03 22:18","market":"us","language":"en","title":"3 Hypergrowth Stocks Expected to Increase Sales 1,185% to 12,629% by 2023","url":"https://stock-news.laohu8.com/highlight/detail?id=2164879370","media":"Motley Fool","summary":"These fast-paced companies should generate jaw-dropping revenue growth over the next three years.","content":"<p>Since the end of the Great Recession in 2009, growth stocks have thrived. Historically low lending rates, an ongoing quantitative easing program designed to weigh down long-term bond yields, and a free-spending Congress have all helped to make cheap capital widely abundant for businesses. This is helping to fuel acquisitions, hiring, and (most importantly) innovation.</p>\n<p>Yet for some companies, their exponential growth is just beginning. For each of the following hypergrowth stocks, Wall Street's consensus sales estimate for 2023, courtesy of <b>FactSet</b>, implies a revenue increase ranging from a low of 1,185% (yes, <i>a low of 1,185%</i>) to a high of 12,629%, compared to 2020 sales.</p>\n<h2>Moderna: Implied sales increase of 1,185%</h2>\n<p>Arguably the best-known name on this list is biotech <b>Moderna</b> (NASDAQ:MRNA). According to Wall Street, Moderna's annual revenue is expected to catapult from the $803.4 million recorded in 2020 to an estimated $10.33 billion in 2023. Interestingly, the $10.33 billion in projected sales for 2023 is about half of the $20.13 billion forecast this year.</p>\n<p>As a lot of you probably know, Modena's success is tied to the development of its coronavirus vaccine mRNA-1273. When the company ran a large-scale study of its COVID-19 vaccine, the results (released in November) demonstrated a vaccine efficacy (VE) of 94% and a strong propensity to keep vaccinated individuals from getting severe forms of the disease. This initial VE made Moderna's COVID vaccine a slam dunk for Emergency Use Authorization in the United States.</p>\n<p>When the company announced its second-quarter operating results on Aug. 5, it stuck to its original forecast of delivering between 800 million and 1 billion doses in 2021, with net product sales of around $20 billion. Next year, Moderna believes it can provide between 2 billion and 3 billion doses. As a reminder, the Moderna vaccine is a two-dose regimen, meaning its 2022 output could fully inoculate 1 billion to 1.5 billion people.</p>\n<p>Also working in Modena's favor is the possibility of booster vaccinations. The mutability of COVID, coupled with a handful of studies suggesting that VE begins waning at the six-month mark, could create a recurring vaccination need globally.</p>\n<p>While Moderna might sound like a surefire growth story, there are still big question marks about its future. For example, even though mRNA-1273 has been wildly successful, it's the only therapy that's generating sales for the company. Moderna's non-COVID pipeline looks to be years away from bringing in meaningful revenue.</p>\n<p>Equally concerning is the likelihood that the COVID vaccine space is going to become crowded. At some point soon, <b>Novavax</b>&nbsp;should join the field with a formidable initial VE of about 90%. It is also working on a combination COVID/influenza vaccine, which would be a differentiator and game changer.</p>\n<p>Not to take anything away from what Moderna has done, but a $150 billion market cap for a company with a single therapy seems awfully risky.</p>\n<h2><a href=\"https://laohu8.com/S/ZGNX\">Zogenix</a>: Implied sales increase of 2,451%</h2>\n<p>Another biotech stock that's expected to generate jaw-dropping sales growth through 2023 is small-cap <b>Zogenix</b> (NASDAQ:ZGNX). If Wall Street's consensus estimate proves accurate, the company's $13.64 million in reported sales in 2020 could grow to $348 million by 2023.</p>\n<p>Like Moderna, there's a single drug that looks to do all of the heavy lifting for Zogenix over the next couple of years: Fintepla. This is a drug targeted at a variety of seizure-related indications. It's already been approved by the Food and Drug Administration to treat Dravet syndrome. And Zogenix has plans to file a supplemental new drug application by the end of the current quarter to expand Fintepla's label to include Lennox-Gastaut syndrome (LGS). Both Dravet and LGS are rare forms of childhood-onset epilepsy. If approved, Zogenix could launch Fintepla for LGS patients in this country by as early as the first half of 2022.</p>\n<p>And Zogenix still isn't done with Fintepla. After hashing out the finer points with the FDA, the company intends to initiate a phase 3 study involving Fintepla as a treatment for CDKL5 deficiency disorder before the end of the year. Thus, organic growth and label expansion opportunities are expected to fuel sales of Fintepla to almost $350 million in three years.</p>\n<p>What'll be particularly interesting is how Zogenix fares against cannabinoid-focused drug developer GW Pharmaceuticals, which was acquired by <b>Jazz Pharmaceuticals</b> (NASDAQ:JAZZ) in May. GW's lead drug, Epidiolex, is a cannabidiol-based treatment that's been approved by the FDA to treat Dravet syndrome and LGS, and it launched in advance of Zogenix's Fintepla. For comparative purposes, Jazz announced that Epidiolex brought home $155.9 million in sales just in the second quarter, although it has an additional indication under its belt (tuberous sclerosis complex) where it won't compete against Zogenix.</p>\n<p>Although Epidiolex appears to have the upper hand now, it's worth noting that seizure-reduction efficacy for Fintepla looked very promising in late-stage clinical trials. To be 100% clear, the GW Pharma and Zogenix studies were never pitted head-to-head, and their baseline parameters are different. Nevertheless, Fintepla led to a 62.3% reduction in mean monthly convulsive seizure frequency compared to placebo at the six-week mark for Dravet syndrome patients.</p>\n<p>Comparatively, Jazz's Epidiolex demonstrated reductions in seizure frequency from baseline of 56% and 47%, respectively, for the lower- and higher-dose treatments in phase 3 studies in Dravet syndrome patients.&nbsp; Suffice it to say, these could be highly competitive indications for the foreseeable future.</p>\n<h2>Marathon Digital Holdings: Implied sales increase of 12,629%</h2>\n<p>Now, if you want pedal-to-the-metal growth, look no further than <b>Marathon Digital Holdings</b> (NASDAQ:MARA). After reporting a meager $4.36 million in sales in 2020, Wall Street anticipates full-year sales will climb to $555 million by 2023. That's an increase of 12,629%.</p>\n<p>If you're wondering how sales growth of this magnitude is possible for a company not involved in drug development, look no further than cryptocurrencies.</p>\n<p>Marathon Digital is a cryptocurrency mining company. It operates a farm of high-powered computing devices designed to solve complex mathematical equations that validate groups of transactions (known as a block) as valid on a digital currency's blockchain. For being the first to validate a block, Marathon is paid a block reward. This reward is typically a set amount of digital tokens from the digital currency being mined.</p>\n<p>In Marathon's case, it's mining <b>Bitcoin</b> (CRYPTO:BTC), the largest cryptocurrency in the world by market cap. Being the first to mine a Bitcoin block results in the company being awarded 6.25 Bitcoin tokens, which were worth a cool $292,000, as of Aug. 30.</p>\n<p>The reason Marathon's sales are skyrocketing so quickly is because it's in the midst of deploying <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the largest Bitcoin-mining operations in the United States. As of the beginning of August, approximately 30,100 miners were operating, with another 103,000 ordered and yet to be installed. By the end of the first quarter of 2022, Marathon should have north of 100,000 miners in operation, with all 133,120 up and running by July 2022.</p>\n<p>Though Marathon is the fastest-growing of these three hypergrowth stocks, it's also arguably the most dangerous investment of this trio. That's because it's entirely dependent on external factors, such as interest in, and the price of, Bitcoin -- and not innovation.</p>\n<p>What's more, the barrier to entry in the cryptocurrency mining space is virtually nonexistent. As time passes, it's going to be tougher for Marathon to successfully mine Bitcoin.</p>\n<p>As the icing on the cake, Bitcoin's block rewards halve every four years. By 2024, only 3.125 Bitcoin tokens will be paid for validating a block. Essentially, Marathon is competing against a growing number of mining companies for a reward that's shrinking. It simply doesn't sound like an operating model with long-term staying power.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Hypergrowth Stocks Expected to Increase Sales 1,185% to 12,629% by 2023</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Hypergrowth Stocks Expected to Increase Sales 1,185% to 12,629% by 2023\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-03 22:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/03/3-hypergrowth-stocks-increase-sales-1185-to-12629/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Since the end of the Great Recession in 2009, growth stocks have thrived. Historically low lending rates, an ongoing quantitative easing program designed to weigh down long-term bond yields, and a ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/03/3-hypergrowth-stocks-increase-sales-1185-to-12629/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","ZGNX":"Zogenix","MARA":"Marathon Digital Holdings Inc"},"source_url":"https://www.fool.com/investing/2021/09/03/3-hypergrowth-stocks-increase-sales-1185-to-12629/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2164879370","content_text":"Since the end of the Great Recession in 2009, growth stocks have thrived. Historically low lending rates, an ongoing quantitative easing program designed to weigh down long-term bond yields, and a free-spending Congress have all helped to make cheap capital widely abundant for businesses. This is helping to fuel acquisitions, hiring, and (most importantly) innovation.\nYet for some companies, their exponential growth is just beginning. For each of the following hypergrowth stocks, Wall Street's consensus sales estimate for 2023, courtesy of FactSet, implies a revenue increase ranging from a low of 1,185% (yes, a low of 1,185%) to a high of 12,629%, compared to 2020 sales.\nModerna: Implied sales increase of 1,185%\nArguably the best-known name on this list is biotech Moderna (NASDAQ:MRNA). According to Wall Street, Moderna's annual revenue is expected to catapult from the $803.4 million recorded in 2020 to an estimated $10.33 billion in 2023. Interestingly, the $10.33 billion in projected sales for 2023 is about half of the $20.13 billion forecast this year.\nAs a lot of you probably know, Modena's success is tied to the development of its coronavirus vaccine mRNA-1273. When the company ran a large-scale study of its COVID-19 vaccine, the results (released in November) demonstrated a vaccine efficacy (VE) of 94% and a strong propensity to keep vaccinated individuals from getting severe forms of the disease. This initial VE made Moderna's COVID vaccine a slam dunk for Emergency Use Authorization in the United States.\nWhen the company announced its second-quarter operating results on Aug. 5, it stuck to its original forecast of delivering between 800 million and 1 billion doses in 2021, with net product sales of around $20 billion. Next year, Moderna believes it can provide between 2 billion and 3 billion doses. As a reminder, the Moderna vaccine is a two-dose regimen, meaning its 2022 output could fully inoculate 1 billion to 1.5 billion people.\nAlso working in Modena's favor is the possibility of booster vaccinations. The mutability of COVID, coupled with a handful of studies suggesting that VE begins waning at the six-month mark, could create a recurring vaccination need globally.\nWhile Moderna might sound like a surefire growth story, there are still big question marks about its future. For example, even though mRNA-1273 has been wildly successful, it's the only therapy that's generating sales for the company. Moderna's non-COVID pipeline looks to be years away from bringing in meaningful revenue.\nEqually concerning is the likelihood that the COVID vaccine space is going to become crowded. At some point soon, Novavax should join the field with a formidable initial VE of about 90%. It is also working on a combination COVID/influenza vaccine, which would be a differentiator and game changer.\nNot to take anything away from what Moderna has done, but a $150 billion market cap for a company with a single therapy seems awfully risky.\nZogenix: Implied sales increase of 2,451%\nAnother biotech stock that's expected to generate jaw-dropping sales growth through 2023 is small-cap Zogenix (NASDAQ:ZGNX). If Wall Street's consensus estimate proves accurate, the company's $13.64 million in reported sales in 2020 could grow to $348 million by 2023.\nLike Moderna, there's a single drug that looks to do all of the heavy lifting for Zogenix over the next couple of years: Fintepla. This is a drug targeted at a variety of seizure-related indications. It's already been approved by the Food and Drug Administration to treat Dravet syndrome. And Zogenix has plans to file a supplemental new drug application by the end of the current quarter to expand Fintepla's label to include Lennox-Gastaut syndrome (LGS). Both Dravet and LGS are rare forms of childhood-onset epilepsy. If approved, Zogenix could launch Fintepla for LGS patients in this country by as early as the first half of 2022.\nAnd Zogenix still isn't done with Fintepla. After hashing out the finer points with the FDA, the company intends to initiate a phase 3 study involving Fintepla as a treatment for CDKL5 deficiency disorder before the end of the year. Thus, organic growth and label expansion opportunities are expected to fuel sales of Fintepla to almost $350 million in three years.\nWhat'll be particularly interesting is how Zogenix fares against cannabinoid-focused drug developer GW Pharmaceuticals, which was acquired by Jazz Pharmaceuticals (NASDAQ:JAZZ) in May. GW's lead drug, Epidiolex, is a cannabidiol-based treatment that's been approved by the FDA to treat Dravet syndrome and LGS, and it launched in advance of Zogenix's Fintepla. For comparative purposes, Jazz announced that Epidiolex brought home $155.9 million in sales just in the second quarter, although it has an additional indication under its belt (tuberous sclerosis complex) where it won't compete against Zogenix.\nAlthough Epidiolex appears to have the upper hand now, it's worth noting that seizure-reduction efficacy for Fintepla looked very promising in late-stage clinical trials. To be 100% clear, the GW Pharma and Zogenix studies were never pitted head-to-head, and their baseline parameters are different. Nevertheless, Fintepla led to a 62.3% reduction in mean monthly convulsive seizure frequency compared to placebo at the six-week mark for Dravet syndrome patients.\nComparatively, Jazz's Epidiolex demonstrated reductions in seizure frequency from baseline of 56% and 47%, respectively, for the lower- and higher-dose treatments in phase 3 studies in Dravet syndrome patients.  Suffice it to say, these could be highly competitive indications for the foreseeable future.\nMarathon Digital Holdings: Implied sales increase of 12,629%\nNow, if you want pedal-to-the-metal growth, look no further than Marathon Digital Holdings (NASDAQ:MARA). After reporting a meager $4.36 million in sales in 2020, Wall Street anticipates full-year sales will climb to $555 million by 2023. That's an increase of 12,629%.\nIf you're wondering how sales growth of this magnitude is possible for a company not involved in drug development, look no further than cryptocurrencies.\nMarathon Digital is a cryptocurrency mining company. It operates a farm of high-powered computing devices designed to solve complex mathematical equations that validate groups of transactions (known as a block) as valid on a digital currency's blockchain. For being the first to validate a block, Marathon is paid a block reward. This reward is typically a set amount of digital tokens from the digital currency being mined.\nIn Marathon's case, it's mining Bitcoin (CRYPTO:BTC), the largest cryptocurrency in the world by market cap. Being the first to mine a Bitcoin block results in the company being awarded 6.25 Bitcoin tokens, which were worth a cool $292,000, as of Aug. 30.\nThe reason Marathon's sales are skyrocketing so quickly is because it's in the midst of deploying one of the largest Bitcoin-mining operations in the United States. As of the beginning of August, approximately 30,100 miners were operating, with another 103,000 ordered and yet to be installed. By the end of the first quarter of 2022, Marathon should have north of 100,000 miners in operation, with all 133,120 up and running by July 2022.\nThough Marathon is the fastest-growing of these three hypergrowth stocks, it's also arguably the most dangerous investment of this trio. That's because it's entirely dependent on external factors, such as interest in, and the price of, Bitcoin -- and not innovation.\nWhat's more, the barrier to entry in the cryptocurrency mining space is virtually nonexistent. As time passes, it's going to be tougher for Marathon to successfully mine Bitcoin.\nAs the icing on the cake, Bitcoin's block rewards halve every four years. By 2024, only 3.125 Bitcoin tokens will be paid for validating a block. Essentially, Marathon is competing against a growing number of mining companies for a reward that's shrinking. It simply doesn't sound like an operating model with long-term staying power.","news_type":1},"isVote":1,"tweetType":1,"viewCount":123,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":812345335,"gmtCreate":1630556918727,"gmtModify":1631883826967,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"Good one","listText":"Good one","text":"Good one","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/812345335","repostId":"1105808841","repostType":4,"repost":{"id":"1105808841","kind":"news","pubTimestamp":1630547089,"share":"https://www.laohu8.com/m/news/1105808841?lang=&edition=full","pubTime":"2021-09-02 09:44","market":"hk","language":"en","title":"Hong Kong: Shares extend gains at open","url":"https://stock-news.laohu8.com/highlight/detail?id=1105808841","media":"AFP","summary":"[HONG KONG] Hong Kong stocks began with another advance on Thursday morning as investors bide their ","content":"<p>[HONG KONG] Hong Kong stocks began with another advance on Thursday morning as investors bide their time ahead of the release of key US jobs data at the end of the week.</p>\n<p>The Hang Seng Index rose 0.67 per cent or 175.23 points to 26,203.52.</p>\n<p>The Shanghai Composite dipped 0.20 per cent or 7.20 points to 3,559.90, while the Shenzhen Composite Index on China's second exchange fell 0.22 per cent or 5.32 points to 2,412.57.</p>","source":"lsy1605843958005","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong: Shares extend gains at open</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong: Shares extend gains at open\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-02 09:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.businesstimes.com.sg/stocks/hong-kong-shares-extend-gains-at-open-3><strong>AFP</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>[HONG KONG] Hong Kong stocks began with another advance on Thursday morning as investors bide their time ahead of the release of key US jobs data at the end of the week.\nThe Hang Seng Index rose 0.67 ...</p>\n\n<a href=\"https://www.businesstimes.com.sg/stocks/hong-kong-shares-extend-gains-at-open-3\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"HSI":"恒生指数"},"source_url":"https://www.businesstimes.com.sg/stocks/hong-kong-shares-extend-gains-at-open-3","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105808841","content_text":"[HONG KONG] Hong Kong stocks began with another advance on Thursday morning as investors bide their time ahead of the release of key US jobs data at the end of the week.\nThe Hang Seng Index rose 0.67 per cent or 175.23 points to 26,203.52.\nThe Shanghai Composite dipped 0.20 per cent or 7.20 points to 3,559.90, while the Shenzhen Composite Index on China's second exchange fell 0.22 per cent or 5.32 points to 2,412.57.","news_type":1},"isVote":1,"tweetType":1,"viewCount":58,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":816635342,"gmtCreate":1630494582086,"gmtModify":1631884041956,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/G13.SI\">$GENTING SINGAPORE LIMITED(G13.SI)$</a>&nbsp;add on some units&nbsp;","listText":"<a href=\"https://laohu8.com/S/G13.SI\">$GENTING SINGAPORE LIMITED(G13.SI)$</a>&nbsp;add on some units&nbsp;","text":"$GENTING SINGAPORE LIMITED(G13.SI)$ add on some units","images":[{"img":"https://static.tigerbbs.com/9fe6678b5e4ece642003d70aab4f16ec","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/816635342","isVote":1,"tweetType":1,"viewCount":70,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":810474341,"gmtCreate":1630000443483,"gmtModify":1704954435581,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>🤑","listText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>🤑","text":"$Alibaba(BABA)$🤑","images":[{"img":"https://static.tigerbbs.com/6c3000d672d4610748b598e9b6f474d2","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/810474341","isVote":1,"tweetType":1,"viewCount":264,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":836992406,"gmtCreate":1629444697605,"gmtModify":1631887920577,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ME8U.SI\">$MAPLETREE INDUSTRIAL TRUST(ME8U.SI)$</a>🤑","listText":"<a href=\"https://laohu8.com/S/ME8U.SI\">$MAPLETREE INDUSTRIAL TRUST(ME8U.SI)$</a>🤑","text":"$MAPLETREE INDUSTRIAL TRUST(ME8U.SI)$🤑","images":[{"img":"https://static.tigerbbs.com/c4d3fadb9d9dc8ae8804d10ac4f6904e","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/836992406","isVote":1,"tweetType":1,"viewCount":43,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":815269105,"gmtCreate":1630681104507,"gmtModify":1632467217325,"author":{"id":"3578570980039527","authorId":"3578570980039527","name":"eunicebok","avatar":"https://static.tigerbbs.com/1edb498503a0c7d2678ef1d8d564496f","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578570980039527","authorIdStr":"3578570980039527"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/815269105","repostId":"1198573200","repostType":4,"isVote":1,"tweetType":1,"viewCount":142,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}